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Biomaterial-free 3D bioprinting is a relatively new field within 3D bioprinting. In 
this implementation, 3D tissues are created from the fusion of 3D multicellular 
spheroids, without requiring biomaterials. This is in contrast to traditional 3D 
bioprinting, which requires biomaterials to carry the cells to be bioprinted, such as 
a hydrogel or decellularized extracellular matrix. In this dissertation, we discuss the 
generation of biomaterial-free 3D cardiac spheroids and 3D bioprinted cardiac 
patches, their mechanical, electrical and biological functional characterization in 
vitro and in vivo for cardiac regeneration. Additionally, we investigated their 
potential use as a disease model using congenital long QT syndrome due to an 
inherited calmodulinopathy as an example, utilizing CRISPR interference to 
shorten abnormally prolonged cardiac action potentials. At the same time, we 
demonstrate the use of virtual reality for the interactive visualization of 
cardiovascular structures and its potential use in pre-surgical planning and patient-
specific precision medicine. 
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1.1. Thesis Statement 
Biomaterial-free 3D bioprinted cardiac tissues show promise for cardiac 
regeneration and cardiac disease modelling.  
 
1.2. Motivation 
Current treatments for heart failure, short of a heart transplant, do not address the 
fundamental issue of the loss of viable contractile cardiac tissue. Thus, cardiac stem 
cell therapy and cardiac tissue engineering have been developed. The generation of 
cardiac tissues may be performed with non-cellular biomaterials and without non-
cellular biomaterials. The first half of this thesis focuses on creating biomaterial-
free 3D bioprinted cardiac tissues using patient-specific human induced pluripotent 
stem cell derived cardiomyocytes and utilize these for cardiac regeneration. 
 
Another important use of engineered cardiac tissues is for disease modeling and 
testing of therapeutic approaches to heart and vascular disease. The use of genome 
editing for correction of heritable heart disease has been hampered by inadequate 





Clustered regularly-interspaced short palindromic repeats (CRISPR)/Cas9-
mediated genome engineering offers a highly promising and specific method of 
correcting inherited gene mutations. This thesis explores using biomaterial-free 3D 
cardiac tissues to model congenital long QT syndrome and the possibility of gene 
correction using CRISPR interference. 
 
1.3. Key Problems 
Three dimensional (3D) cell culture and the creation of 3D multicellular spheroids 
have been around for almost five decades, but it is only recently, that spheroids are 
being employed increasingly for the purpose of tissue engineering  (12) and tissue 
regeneration (13). 3D multicellular spheroids offer the opportunity to create 3D 
tissue without the use of biomaterials. Advances in 3D bioprinting technology have 
led to the new field of biomaterial-free 3D bioprinting (3, 14-18).  
 
Traditional biomaterial-dependent 3D bioprinting (19) has limitations, such as the 
intrinsic stress to live cells by heat exposure or shear stress during 3D bioprinting, 
isolation of 3D bioprinted cells from their neighbors, and the risk of foreign 
material in the biomaterials, which may be relatively contraindicated for eventual 
intended clinical use. In contrast, using spheroids as building blocks for 3D 
bioprinting is gentler (19) and may recapitulate the developmental biological 






This thesis makes the following contributions: 
In Chapter 2, we present the principles of spheroid preparation for creation of 3D 
cardiac tissue using biomaterial-free 3D bioprinting, 
In Chapter 3, we present the generation of biomaterial-free 3D cardiac tissue using 
3D bioprinting and characterized them in isolation and investigated their potential 
use as a disease model. 
In Chapter 4, we present the utilization of these 3D patches for cardiac repair in 
three rodent surgical models, as ways of delivering cardiac stem cells to the heart. 
In Chapter 5, we explore the use of biomaterial-free 3D cardiac tissue to model 
congenital long QT syndrome. 
In Chapter 6, we explore the use of 3D segmentation, 3D printing and 3D virtual 
reality in cardiovascular medicine and demonstrate how patient-specific 
customized cardiac tissue with complex shapes and geometries can be created using 
biomaterial-free 3D bioprinting. 







Principles of spheroid preparation for creation of 3D cardiac tissue using 
biomaterial-free 3D bioprinting 
 
2.1 Introduction 
In this chapter, we discuss the principles and important considerations for creation 
of 3D cardiac tissue from multicellular spheroids using biomaterial-free 3D 
bioprinting based on our experience with the Regenova 3D bioprinter (Cyfuse Inc, 
Tokyo, Japan). We divide the protocol and principles into 4 distinct steps: Spheroid 
optimization (Step 1), spheroid dislodgement (Step 2), spheroid transfer (Step 3) 
and spheroid fusion (Step 4). These are important considerations for biomedical 
engineers, who seek to use existing spheroid-based 3D bioprinters and also create 
the next generation of spheroid-based 3D bioprinters. 
 
2.2 Spheroid optimization / creation  
The principle behind spheroid optimization is to create a 3D multicellular spheroid 
(Figure 1) that is: 
• Not too adherent to the bottom of the ultra-low attachment U-well, that will 





• Compact and strong enough to prevent disintegration during spheroid transfer 
(Step 3) 
• Appropriately sized to ensure adequate fusion between spheroids (Step 4, 
Figure 2) 
For this, the following parameters (non-exhaustive list) may be adjusted to obtain 
the optimized spheroid. Our parameters (3) are stated in parentheses. 
• Type of cells (hiPSC-CMs, FBs, HUVECs) 
• Cell ratio (CM:FB:EC 70:15:15) 
• Number of cells seeded into 96-well plate for one spheroid (33,000 cells) 
• Duration of 3D culture (72 hours) 
The threshold of what is considered an optimized spheroid varies widely. For us, 
these are the parameters of the spheroid that we consider acceptable for bioprinting. 
• Resultant spheroid diameter (500-600 µm) 
• Resultant cell viability within spheroid (93.3%) 
• Spheroid circularity/roundness (70%) 






Figure 1: 3D cardiospheres. Cells in each well aggregate at the bottom of ultra-low 
attachment 96-well U-bottom plates to form spheroids by gravity. These spheroids 
can be visually inspected under light microscopy, where they should appear circular 
by two-dimensional projection (14). 
 
2.3 Spheroid dislodgement 
The principle behind spheroid dislodgement is that the spheroid created should be 
ideally as easy to pick up as possible, without the need for too much damage to the 
shape of spheroids in this process and troubleshooting. The following list includes 
what we usually consider when we seek to establish the optimal conditions for the 





• Spheroid culture conditions: We seek to optimize the spheroid culture 
conditions by modifying parameters as documented in the previous section. In 
addition, the type of cells (adult or neonatal), maturity/stemness (in the case of 
stem cells), passage number, timing of harvesting cells, culture duration, and 
culture medium (e.g. addition of growth factor) also affect the adhesion of 
spheroids to the bottom of the well. For example, from our experience, younger, 
immature hiPSC-CMs 3 weeks post-differentiation adhere better to each other 
and form spheroids faster, than older, more mature hiPSC-CMs 2-3 months 
post-differentiation. Spheroids made from younger, immature hiPSC-CMs also 
appear more compact. Spheroids that are cultured for a longer duration are more 
adherent to the bottom of the well. 
• Cell types within the spheroids: Cell types are inherently different, and some 
cell types may secrete more extracellular matrix or be “stickier” or attaching to 
the bottom of the well, than others. For example, from our experience, reduction 
in the proportion of fibroblasts in the spheroid, in particular, can decrease the 
adhesion of spheroids to the bottom of the well. This parameter may be difficult 
to modify if a specific type of tissue with a specific cell type ratio is desired to 
answer a scientific question, and that resultant spheroid is inherently more 
adherent to the bottom of the well. Thus, other methods listed above and below 





• Mechanical force (such as tapping, hitting) may be required to dislodge the 
spheroid from the bottom of the well. 
• Addition of exogenous biomaterial: For situations where cells do not adhere 
well to each other despite supporting cells that secrete ECM such as fibroblasts, 
exogenous biomaterial may be needed for spheroid creation. 
 
2.4 Spheroid transfer 
There are several methods to transfer spheroids, such as by machine-generated 
mechanical suction or manual pipetting. The principle behind spheroid transfer is 
that the spheroids need to be sufficiently compact in order to be picked up and 
moved during bioprinting. The way to increase spheroid compaction is generally 
the opposite of what was discussed in previous section. For example, increasing 
culture duration and fibroblast cell ratio will lead to more compact spheroids, at the 
cost of the spheroids being more adherent to the bottom of the wells. This however, 
is not always the case, as how compact spheroids are really depends on the shape 
in which the spheroids form. While we hope that spheroids form as spheres and 
gradually compact, they may be more elliptical or “pancake”-like, especially if they 
were strongly adherent to the bottom of the well in the early stages of spheroid 
formation (first 24 hours), due to the cell types / viability of the cells that were used. 
Spheroid reoptimization may be needed, if this step fails on multiple occasions and 





2.5 Spheroid fusion 
The spheroids must fuse in order to form an organized 3D tissue. Spheroid size may 
be one of the most important factors for the fusion of spheroids. The principles 
behind spheroid fusion are: 
• There must be sufficient overlap of spheroids of at least 50 µm, if a hypothetical 
line is drawn connecting the centers of the two spheroids, when inspected from 
the top of the needle array (Figure 2), to begin the fusion process. 
• If the spheroids are too large and there is too much overlap, adjacent spheroids 
may be pushed away from each other, resulting in the creation of disorganized 
and fragile tissue. 
• There must be sufficient time for spheroids to fuse [we culture for 3 days]. 
• The fusion process can be impaired if there are misplaced or lost spheroids 
during 3D bioprinting.  
• As the 3D bioprinting process is not completely sterile, we recommend the 
addition of antibiotics immediately after 3D bioprinting, such as 
Penicillin/Streptomycin or Normocin to reduce contamination during the fusion 
process. Antibiotics may be added during spheroid creation, if there are 
significant issues with contamination despite maximal precautions and the 
addition of antibiotics immediately after 3D bioprinting. We add Normocin at 
1:500 to our cell media. However, the addition of antibiotics to cell culture 





created and is stable (not disintegrating), is not recommended as this may lead 
to antibiotic resistant bacteria and long term Normocin exposure may harm the 
cells. The required accessories of the 3D bioprinter should be assembled before 






Figure 2: Cardiosphere dimensions and the degree of cardiosphere overlap 





Representative images of 3D bioprinted cardiac patches (CM:FB:EC 70:15:15) 
with overlap at least 50 µm (A), some overlap, 1 to 50 µm (B) and no overlap (C), 
immediately after printing, after decannulation and after maturation. Scale bar: 
1000 µm. D: Cardiosphere diameters immediately before printing for 3D bioprinted 
cardiac patches in Panels A (504.6 ± 30.6 µm) (n = 81), B (413.1 ± 21.6 µm) (n=81), 
C (382.4 ± 16.1 µm) (n = 65) respectively (3). 
 
2.6 Conclusion 
A detailed laboratory protocol detailing every step with accompanying notes is 
available at the following reference (3), after more than 2 years of experience doing 
biomaterial-free spheroid-based 3D bioprinting. We have sought to document 
principles, tips and advice, discovered from repeated experimental trial and error, 
in detail. It is written in a spheroid-centric way, to emphasize the importance of the 
3D cell spheroid as a transient building block, and the source of cells that comprise 
the final 3D bioprinted tissue construct, through the process of tissue engineering.  
 
We suggest that the ideal process of tissue creation using biomaterial-free spheroid-
based 3D bioprinting is based on the dynamic balance and flexible interactions of 
the four steps we have outlined. We use the Goldilocks principle in pursuit of the 
ideal spheroid for 3D bioprinting (not too small, not too large, not too compact, not 





bioprinter and the cell types to be bioprinted. This conceptual breakdown serves as 
a guide to understand the principles behind biomaterial-free spheroid-based 3D 
bioprinting and develop the next generation of 3D bioprinters. 
 
There are also technical limitations in existing biomaterial-free 3D bioprinters that 
have not been covered in this chapter. For example, the fixed distance of 400 µm 
between adjacent needles inherently places the thickness of a 3D bioprinted single-
layer patch to be around 500 µm, as that is the ideal spheroid diameter for 3D 
bioprinting (Figure 2). Improved temperature control, improved sterility within the 
3D bioprinter, ability to self-sterilize, less reusable parts that require autoclaving, 
increased speed of the robotic moving equipment (Video B.1) and the ability to use 
culture media instead of PBS, are all factors that can improve 3D spheroid and 3D 
bioprinted patch viability, that might be helpful modifications for future 






Generation of biomaterial-free 3D cardiac tissue and characterization in 
isolation and potential use as a disease model  
 
3.1. Introduction 
Heart failure is common, debilitating and ultimately lethal malady which consumes 
billions of dollars and thousands of lives each year (20). Current treatments for 
heart failure (21) alleviate symptoms and modestly prolong life but are palliative as 
they do not address the fundamental mechanism of the loss of functional cardiac 
tissue. Cellular therapy aimed at improving cardiac function and regenerating new 
myocardium, has been extensively investigated for cardiac repair (22). Despite 
numerous preclinical and clinical studies (23-28) performed to assess the ability of 
various stem cell populations to improve cardiac function and reduce infarct size, 
many important issues remain unresolved, and no cell therapy to date has been 
demonstrated conclusively to be effective. There are significant limitations to cell 
therapy in terms of cell retention, survival of the engrafted cells, cell differentiation, 
and integration of transplanted cells with host tissue (29).  
 
In order to overcome the current issues in cell-based treatment of heart failure, the 





progenitor cells, 2) improvement of retention and engraftment of delivered cells 
with sufficient nutritional supply, 3) Development of biomaterial that can directly 
improve the contraction of cardiac tissue. Recent advances have applied 3D 
printing technologies to biocompatible materials, cells and supporting components 
with great promise for artificial organ printing and regenerative medicine 
applications (30). 3D bioprinting of myocardial tissue has utilized biomaterials (31, 
32), such as polycaprolactone (PCL) (33), sodium alginate (34), 3D printed 
gelatin/methylbenzene sulfonate (MBS) extracellular matrix (ECM) scaffolds (35) 
or decellularized ECM to generate platforms for extrusion-based printing (36).  The 
use of biomaterials faces challenges, such as immunogenicity, host inflammatory 
responses, fibrous tissue formation, biomaterial degradation and toxicity of 
degradation products, that affect the long term function of the engineered tissue 
construct (37). 
 
We have developed a method to create 3D bioprinted cardiac tissue without the use 
of biomaterials (14) (Figure 3), by assembling multicellular cardiospheres 
consisting of human induced pluripotent stem cell derived cardiomyocytes (hiPSC-
CMs), human adult ventricular cardiac fibroblasts (FBs) and human umbilical vein 
endothelial cells (ECs) using a 3D bioprinter. We hypothesize that novel 
biomaterial-free 3D printed cardiac patches will exhibit mechanical integrity with 






Figure 3: Schematic overview of biomaterial-free cardiac 3D bioprinting process. 
A. Cells (CMs, FBs, ECs) are aggregated in ultra-low attachment 96-well plates to 
form cardiospheres. B. The desired 3D structure to be bioprinted is designed using 
computer software. C. The 3D bioprinter picks up individual cardiospheres using 
vacuum suction and loads them onto a needle array. D. Cardiospheres are allowed 
to fuse. The 3D bioprinted cardiac tissue is then removed from the needle array and 
cultured further to allow the needle holes to be filled in by surrounding tissue. 
 
3.2. Methods 
3.2.1 Generation of hiPSC-CMs 
Human IPSCs (reprogrammed from the peripheral blood mononuclear cells of a 
healthy donor) were differentiated into cardiomyocytes, by temporal modulation of 





No. 4423, and IWR-1, Sigma-Aldrich, Cat. No. I0161). We only used hiPSC-CMs 
from regions of 2D cultures that were beating to create cardiospheres. In addition, 
we also performed optical mapping on the hiPSC-CMs as 2D monolayers for 
quality control and to ensure that hiPSC-CMs were able to form electrical 
connections in vitro (see Supplementary Figure A.1, Video B.1). 
 
3.2.2 3D bioprinting of cardiac patches 
We have previously published our protocol for 3D bioprinting of cardiac patches 
using only cardiospheres, without the use of biomaterials (14) (Video B.2). In brief, 
hiPSC-CMs were co-cultured with human umbilical vein endothelial cells (Lonza, 
Cat. No. CC-2935) and human adult ventricular cardiac fibroblasts (FB) (Sciencell, 
Cat. No. 6310) for 72 hours to form mixed cell spheroids (“cardiospheres”) (see 
Supplementary Figure A.2). A 3D bioprinter (Regenova, Cyfuse Biomedical K.K., 
Tokyo, Japan) was then used to construct biomaterial-free cardiac patches (Figure 
3). The desired 3D geometry (one single layer of cardiospheres) was prepared using 
the 3D design software of the 3D bioprinter. The 3D bioprinter first identified the 
locations of the cardiospheres within U-wells of the ultra-low adhesion 96-well 
tissue culture plate by automated software detection. Then, a robotic arm used 
suction to pick up, transfer and load the cardiospheres individually onto a needle 
array in exact spatial coordinates, according to the pre-specified 3D design, in a 





calibrated by automated software-aided visual detection of the needle tips to ensure 
precision and accuracy. Once bioprinted, the cardiac patch was allowed to mature 
for 72 hours in culture with the needle array in place, while placed on a shaker 
(Compact Digital Microplate Shaker, Thermo Scientific, Waltham, MA) at 150 
rounds per minute (rpm) in the incubator. During this time, the cardiospheres fuse. 
Then the needle array was removed (decannulation) and the cardiac patches were 
cultured for variable times before final evaluation and assessment. 
 
3.2.3 Optical mapping 
Cardiac patches were placed in a 35 mm dish and stained with 10 M of the voltage-
sensitive dye di-4-ANEPPS (Sigma-Aldrich Corp., St. Louis, MO) in Tyrode’s 
solution (135 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 1mM MgCl2, 0.33 mM 
NaH2PO4, 5mM HEPES, and 5mM glucose (Sigma-Aldrich Corp., St. Louis, 
MO)), supplemented with 20 M of the contraction inhibitor blebbistatin (Sigma-
Aldrich Corp., St. Louis, MO) for 10 minutes at 37C. Patches were rinsed twice 
with Tyrode’s with blebbistatin before being transferred to a heated stage where 
they were allowed to equilibrate at 37C for at least 5 minutes before the start of 
pacing. Samples were point paced with at least 30 stimulus pulses over a range of 
basic cycle lengths, starting from 2000 ms and decrementing until loss of capture. 
Optical recordings during pacing were obtained using a 100x100 pixel CMOS 





Optical mapping data was analyzed using custom MATLAB scripts. Recordings at 
each pixel were de-noised using a previously described method (39) to regulate 
total signal variance and convolved with a 5x5 spatial Gaussian filter. Activation 
times, defined as the maximum of the derivative of membrane potential (dV/dt), 
were calculated as previously described (40). Histograms of local conduction 
velocities were generated for each patch and were fitted to a Gaussian curve. The 
mean of the Gaussian was defined as the average conduction velocity (CV). For 
each patch, action potential durations at 30 and 80 percent repolarization (APD30 
and APD80) were calculated for all local traces over the recording area and fit with 
Gaussian curves to determine the mean value for each sample, as described for CV 
measurements.  
 
3.2.4 Flow Cytometry 
Flow cytometry was performed on single cells dissociated from 2D hiPSC-CM 
monolayers using a flow cytometer (Accuri C6 Flow Cytometer, BD Biosciences, 
San Jose, CA) using the antibodies VCAM1, VEGFR2, PDGFRβ (BD Biosciences, 
San Jose, CA) 
 
3.2.5 Immunofluorescence  
Printed tissues were fixed in 4% paraformaldehyde, embedded in O.C.T. compound 





tissues were then washed in PBS, incubated in 0.5% Triton X for 5-10 minutes, 
washed in PBS again and blocked for one hour using 10% goat serum. Primary 
antibodies to the cell protein or biomarker of interest (Troponin, Alpha-Actinin, 
Connexin 43 (Cx43), Human Nucleic Acid (HNA), Wheat Germ Agglutinin 
(WGA)) were incubated with the sections overnight. Removal of unbound primary 
antibodies was accomplished by washing using PBS. Secondary antibodies were 
incubated with the sections for one hour before washing using PBS and mounting 
using Vectashield Antifade Mounting Medium with 4',6-diamidino-2-phenylindole 
(DAPI) (Vector Laboratories, Burlingame, CA).  
 
3.2.6 Immunohistochemistry 
High-temperature antigen retrieval and paraffin removal were performed by 
immersing slides in Trilogy (Cell Marque, Hot Springs, AR) in a pressure cooker 
until the chamber reached 126°C and 23 psi. A Dual Endogenous block (Dako, 
Carpinteria, CA) was applied for 5 minutes. Slides were incubated with antibodies 
to vimentin (Cell Signaling Technology, Danvers, MA), cardiac troponin T 
(Abcam, Cambridge, MA), or CD31 (Thermo Fisher, Waltham, MA), followed by 
addition of a mouse or rabbit HRP detection system (Leica Biosystems, Chicago, 
IL). Finally, slides were stained with a DAB substrate (Vector Lab, Burlingame, 






3.2.7 Cell Viability Assay 
Cell viability of the 3D bioprinted cardiac tissue was determined using TUNEL 
assay (DeadEnd™ Fluorometric TUNEL System, Promega, Madison, WI) on 3D 
bioprinted cardiac tissue that was removed from cell culture media and immediately 
embedded in O.C.T. compound (Tissue-Plus™, Thermo Fisher, Waltham, MA), 
then cross-sectioned into 8 µm sections and stained. Live and dead cell counts were 
counted using ImageJ software on representative images in the periphery (n=4) and 
the center (n=4) of the 3D bioprinted cardiac tissue. 
 
Cell viability of the cardiospheres was determined using a kit that marks live cells 
(the presence of ubiquitous intracellular esterase activity enzymatically converts 
nonfluorescent cell-permeant calcein AM to green fluorescent calcein) and dead 
cells with (ethidium homodimer enters dead cells with damaged membranes and 
binding to nucleic acids with red fluorescence) (LIVE/DEAD® 
Viability/Cytotoxicity Kit for mammalian cells #L3224, Thermo Fisher, Waltham, 
MA). Imaging of cardiospheres was then performed using a confocal laser scanning 
microscope (Zeiss LSM800 with upgraded GaAsP detectors).  
Cell viability of the cardiospheres was also measured using a 3D cell viability assay 
(CellTiter-Glo #G9681, Promega, Madison, WI). Briefly, the spheroids/cells were 





room temperature for 25 minutes to stabilize luminescence. It was then read by a 
plate reader (Molecular Devices Spectra MAX Gemini EM). 
 
3.2.8 Imaging 
Photographs of 3D bioprinted cardiac tissue and the 3D bioprinting process were 
acquired using an 8 MP digital camera. 3D bioprinted cardiac patches were imaged 
using inverted microscopes (EVOS XL, EVOS FL Cell Imaging System, Thermo 
Fisher, Waltham, MA). Confocal microscopy was performed using an upright Zeiss 
LSM 700 or LSM 510 Meta with oil-immersion objectives ranging from 40× to 
63× using spectral lasers at 405-, 488- and 561-nm wavelengths. ImageJ software 
(NIH, Bethesda, MD) was used to generate composite microscopy images by 
combining fluorescent channels.  
 
3.2.9 Statistics 
For all experiments, data was represented graphically as bar or line charts with error 
bars, representing the mean with the standard error of the mean, using Prism 7 
(GraphPad, La Jolla, CA). Statistical analysis of CV, APD, minimum pacing cycle 
length and cell viability was performed with unpaired 2-tailed t-tests. A p value less 







3.3.1 hiPSC-CMs and cardiosphere formation 
We generated hiPSC-CMs that were enriched for CM cell surface markers, as 
demonstrated by flow cytometry performed on hiPSC-CMs 14 days post 
differentiation (Figure 4). VCAM1, a cardiomyocyte marker (41), was 
predominantly expressed (93.2%). Of the 6.8% remaining cells, 1.8% and 1.4% 
were positive for the vascular and fibroblast markers VEGFR-2 and PDGFRβ. 
Further hiPSC-CM quality control measures (spontaneous beating phenotype, 
electrical connections by voltage optical mapping) are described in Methods. 
 
Figure 4: Cell surface markers expressed by hiPSC-CMs used to generate 
cardiospheres. A-C: Flow cytometry analysis using VCAM1 (A), VEGFR-2 (B), 
PDGFRβ (C) surface markers. 
 
In order to create cardiospheres that were amenable to 3D bioprinting, we had to 
optimize the cell types, cell ratios and total cell numbers required for aggregation 





previous report demonstrating prevascularization of cardiac patches using 
endothelial cells (42). Cardiospheres did not form when only hiPSCs or hiPSC-
CMs were used; (Supplementary Figure A.2, Figure 5A-B). In the case of hiPSCs 
(Figure 5A), a loose, soft, gel-like cell aggregate, that is easily disrupted, formed 
within 48 hours. In the presence of FBs and ECs, hiPSC-CMs formed cardiospheres 
in 24 hours and these cardiospheres started beating spontaneously by 48 hours 
(Figure 5C-D). The spheroid beating rate was 28.7 ± 7.9 beats per minute (mean ± 
SD) (Figure 5E-G). We then created cardiospheres of different cell ratios 
(CM:FB:EC 85:0:15, 70:15:15, 45:40:15) and various cell densities (5, 10, 20, 30, 
40, 60 thousand cells/cardiosphere), and measured their diameters after 3 days of 
culture (Figure 5H) and 5 days of culture (Figure 5I), to determine the mean 










Figure 5: Cell type, number and ratio determine cardiosphere integrity. A-B: 
hiPSCs (100%) (A) and hiPSC-CMs (100%) (B) do not form spheroids after 48 
hours in ultra-low attachment 96-well plates (Top 10,000 cells/well. Bottom 40,000 
cells/well). C-D: hiPSC-CM:FB:EC ratio 70:15:15 (C) and 45:45:10 (D): 
Cardiospheres form in 24 hours and start beating in 48 hours. Scale bar panels A-
D: 400 µm. E-G: Beating rate of cardiospheres composed of hiPSC-CM:FB:EC 
ratio of 45:40:15 (E), 70:15:15 (F) and 85:0:15 (G) at various cell numbers per 
cardiosphere, in beats per minute (bpm). H-I: Mean diameter (µm) of cardiospheres 
of various cell ratios (hiPSC-CM:FB:EC) and various cell numbers, after 3 days 
(H) and 5 days (I) of culture. 
 
Sufficient overlap of cardiospheres was needed to form mechanically stable 3D 
bioprinted cardiac patches (Figure 2A-B, Figure 6). When the borders of the 
cardiospheres did not overlap sufficiently, the subsequent fusion of cardiospheres 
was poor and, upon decannulation from the needle array, the patches tended to 
disintegrate (Figure 2C). Interestingly, even though there were holes and partial 
disintegration of the patches, the unfused areas of the patches filled in and fused 
subsequently in culture after decannulation to form an intact patch, though the final 
patch size was smaller with an altered shape. Combining information about the 
amount of cardiosphere overlap needed (Figure 2D) with data about cardiosphere 





subsequent 3D bioprinting experiments, to create cardiospheres between 500 to 550 
µm in diameter, that had sufficient overlap for mechanical integrity of the 3D 
bioprinted cardiac patches. Further assessment of cell viability of the cardiospheres 
(33,000 cells per cardiosphere, CM:FB:EC ratio 70:15:15) can be found as 
Supplementary Figure A.4.  
 
Figure 6: Creation of 3D cardiac patches exhibiting mechanical integration of 
spheroids. A 3D bioprinted cardiac patch immediately after removal from the 
needle array with visible needle holes (left). At this time, the boundaries between 
the spheroids had already become indistinct and the patch had already begun 
beating spontaneously, thus the spheroids had become mechanically integrated. 





needle array were filled in by surrounding tissue (right), and the patch continued 
beating spontaneously. Scale bar: 1 mm.  
 
3.3.2 Electrophysiological studies of 3D bioprinted cardiac patches.  
It has previously been shown that the proportion of cardiomyocytes within a 
cardiosphere is directly proportional to the dimensional change of the cardiosphere 
during contraction and the addition of fibroblasts to the cardiospheres improves 
printed patch integrity (42). We were interested in the effect of fibroblasts on 
electrophysiological properties of 3D bioprinted patches, thus we chose three 
groups of cell ratios to study (CM:FB:EC ratio of 70:0:30, 70:15:15 and 45:40:15).  
 
3D bioprinted cardiac patches of CM:FB:EC cell ratios 70:15:15 and 70:0:30 could 
be  paced from a point source  with  electrical capture and propagation across the 
entire patch, as indicated by isochronal activation maps obtained by voltage optical 
mapping one week after bioprinting (43) (Figure 7A-B) (n=10). When a CM:FB:EC 
cell ratio of 45:40:15 was used, functional block in the middle of the patch, with 
slower conduction was occasionally observed (Figure 7C) (n=3). Conduction 
velocity (CV), APD30 and APD80 (44) were calculated for patches (CM:FB:EC 
70:0:30 and 70:15:15) at pacing cycle lengths ranging from 2000 to 600 ms (Figure 
7D-G). Patches with CM:FB:EC ratio of 45:40:15 were excluded due to the 





70:15:15 group (n=6), compared to the 70:0:30 group (n=4) but this did not reach 
statistical significance (Figure 7E). APD30 were significantly longer in the 70:15:15 
group (n=6), compared to the 70:0:30 group at the longer pacing cycle lengths (n=4) 
(Figure 7F). APD80 was significantly longer in the 70:15:15 group (n=6), compared 
to the 70:0:30 group at all pacing rates (n=4) (Figure 7G). The minimum pacing 
cycle length producing capture was not statistically different between the 70:15:15 
group and the 70:0:30 group (Figure 7H). The data are consistent with differing 
degrees of electrical integration in patches of different cellular composition.  
 
Figure 7: Optical mapping of 3D bioprinted cardiac patches demonstrates electrical 
integration of component cardiospheres. A-C: Representative isochronal activation 
maps of 3D bioprinted cardiac patches with CM:FB:EC ratios of 70:15:15, 70:0:30 
and 45:40:15, respectively. White pulse symbol indicates site of the stimulus 





1 mm. D: Representative action potential recording of a 3D bioprinted cardiac 
patch, with the circles indicating APD30 (blue circle) and APD80 (red circle). E-H: 
Mean conduction velocity (E), APD30 (F), APD80 (G) and minimum pacing cycle 
length (CL) with 1:1 capture (H) of 3D bioprinted cardiac patches (n=10). 
 
3.3.3 Imaging of 3D bioprinted cardiac patches.  
The electrophysiological data suggest high cell viability and TUNEL staining 
demonstrates a mean cell viability of 93.3 ± 5.4% one week after bioprinting 
(Figure 8A). At this time, the 3D cardiac patches stain positively for markers of 
each cell type that was incorporated into the cardiospheres: troponin T for CMs, 
vimentin for FBs and CD31 for ECs (Figure 9A-C). Interestingly, the pattern of 
CD31 staining suggests the formation of rudimentary blood vessels (Figure 9C). 
Histological stains (H&E and Masson Trichrome) of 3D bioprinted cardiac patches 
illustrate the presence of collagen indicating the deposition of extracellular matrix 
after printing of the patch (Figure 9D-E). Confocal microscopy revealed the 
presence of connexin 43 (Cx43), a gap junction protein that allows for electrical 
coupling between cardiomyocytes, localized to cell-cell borders between troponin 
T (Figure 8B) and alpha-actinin (Figure 8C) positive hiPSC-CMs. The distribution 
of the total number of cells is also comparable between the periphery and the center 






Figure 8: Confocal microscopy of 3D bioprinted cardiac patches. 
Immunofluorescence of 3D bioprinted cardiac patches (CM:FB:EC 70:15:15) using 
confocal microscopy. A: TUNEL (Green) DAPI (Blue), Scale bar: 40 µm. Mean 
patch viability (Live cells/Total cells) = 93.26 ± 5.42% (Mean ± SD). B: Cx43 
(Red), troponin T (Green), DAPI (Blue). Scale bar: 20 µm. C: Cx43 (Red) Alpha-
actinin (Green) DAPI (Blue), Scale bar: 20 µm. Troponin and α-actinin staining 
demonstrate the development of sarcomeres. Cx43 exhibit punctate staining and 







Figure 9: Immunohistochemistry and histology of 3D bioprinted cardiac patches. 
Tissue staining of 3D bioprinted cardiac patches (CM:FB:EC 70:15:15) with 
antibodies to troponin T (A), vimentin (B) and CD31 (C).  D: H&E and E: Masson 
Trichrome stain. CD31 staining suggests the formation of rudimentary blood 
vessels. The tissues are highly cellular and Masson stain reveals the presence of 
fibrous tissue in the matrix.  Scale bar: 100 µm. 
 
3.4. Discussion 
Biomaterial-free 3D printing of cardiac tissue avoids the problems associated with 
using biomaterials (37) (immunogenicity, fibrous tissue formation, biomaterial 
degradation, toxicity of degradation products), and also overcomes the difficulties 





cardiospheres, as well as control the distance between cardiospheres by previously 
described methods. If cardiospheres are too far apart, tissue voids will be created in 
the final construct. On the other hand, if cardiospheres are too close together, they 
may stack and create areas in the patch with increased thickness.  
 
Using our method, we were able to position cardiospheres in precise coordinates, 
in a flexible grid configuration (Figure 2), bioprinting patches of uniform shape and 
thickness (Figure 2A-B, Supplementary Figure A.3). This results in a more uniform 
tissue at the macroscopic and microscopic level, compared to previous reported 
random self-assembly of cardiospheres (42). Continuous electrical conduction 
(Figure 7A, B) also suggests uniform cardiosphere integration. 
 
In the case of cardiosphere self-assembly (42), it may also be difficult to select 
individual cardiospheres. Our method allows for the selection of individual 
cardiospheres, for example, we can instruct the bioprinter to only use cardiospheres 
between 450 µm to 550 µm in diameter for bioprinting and reject the use of all 
others that do not fit this criterion. In addition, 3D bioprinting allows for complex 
3D constructs of various geometries (e.g. tubes, rings, etc.) and thicknesses 
(number of layers) to be created, as well as 3D constructs made of cardiospheres of 
different cell types, cell ratios and total cell numbers. These complex shapes and 





tissue engineering, such as cell sheet technology (45-48), bioreactor culture systems 
(49, 50), including rotating orbital shakers (51, 52), rapid inter-cell click ligation 
process (53) and cardiosphere self-assembly (42). 
 
In spite of the absence of biomaterials, we were able to achieve high cell density 
and functional cell contacts, creating a spontaneously beating cardiac tissue. Within 
3 days of printing, our 3D bioprinted cardiac patches were spontaneously beating 
(while on the needle array), and after removal from the array, within another 2 days, 
the voids in the patch fused and the cardiospheres were electrically integrated 
(Figure 7). Due to the absence of exogenous biomaterials in our 3D bioprinted 
cardiac patches, the local 3D microenvironment may be more physiological (54, 
55), and allow for more cell-cell coupling and communication.  
 
The printed patches reveal high cell density; however, a potential drawback is low 
viability of cells in the bioprinted tissue due to lack of vascularization. Importantly, 
we have demonstrated the presence rudimentary blood vessel formed by ECs in the 
3D bioprinted cardiac patches (Figure 9C) with a cell viability in the patch 
exceeding 90% (Figure 8A).  
 
We recognize concerns regarding diffusion limitation. While the 3D bioprinted 





measured at a single point in time is high, this does not imply that there is no cell 
death and cell turnover. It is possible that several tissue related factors improve 
oxygen and nutrient diffusion including spontaneous contraction of the patches, the 
presence of primordial vasculature (formation of primitive blood vessel-like 
structures), less compaction (especially immediately after printing) and 
prevascularization of the cardiospheres (inclusion of ECs in spheroids) (42). The 
cells in the cardiospheres may also exhibit greater tolerance to lower oxygen 
tension and hypoxic conditioning (56). 
 
In forming cardiospheres (42, 57), two important factors must be considered: 1) the 
ratio of cell types, and 2) cell number. Cardiospheres were not formed when iPSCs 
or hiPSC-CMs alone were used (Figure 5A-B); in contrast, wells containing 
cardiomyocytes co-cultured with at least 15% ECs or FBs formed spheroids (Figure 
5C-I). We kept the EC proportion constant at 15% on the basis of previous reports 
of successful prevascularization of cardiac patches using ECs as a component (42). 
Cardiosphere dimensions depended on cell number and varied slightly with cell 
composition (Figure 5). After optimization, we chose to use 33,000 cells per 
cardiosphere, to produce cardiospheres that overlap and form patches consistently 
(Figure 2, Figure 5G, H). We found that an overlap of 50 µm, on each side of the 





between cardiospheres and for an intact cardiac patch to form 3 days after printing 
(Figure 2A).  
 
Fibroblasts may help to stabilize patch structure, but these cells are likely to impact 
myocyte contacts and slow CV. In 3D bioprinted cardiac patches with a higher 
fibroblast ratio, there is lower CV, and significantly longer APD30 and APD80 
(Figure 7F-G), suggesting that fibroblasts inhibit electrical coupling of myocardial 
cells. We also noted the presence of functional block (see Video B.3) and 
arrhythmic activity in the middle of the patches with higher fibroblast numbers. A 
recent study reported similar findings of prolonged APD and increased 
arrhythmogenicity in in vitro cultures of embryonic stem cell-derived 
cardiomyocytes co-cultured with adult cardiac fibroblasts, compared with co-
culture with mesenchymal stem cells (58). Nonetheless, a non-myocyte cell source, 
such as fibroblasts, is needed to produce ECM. hiPSC-CMs and ECs will suffice in 
creating 3D bioprinted cardiac patches, but the slow elaboration of matrix by ECs 
results in friable patches that cannot be implanted. From a regenerative and 
biomimicry point of view (59, 60), the presence of both fibroblasts and endothelial 
cells is needed, and these cell types have been traditionally used by cardiac tissue 






The optical mapping results corroborate the confocal imaging finding, which shows 
the presence of connexin 43 (Cx43), the main connexin in ventricular myocardium 
allowing for electrical coupling, expressed between troponin T and alpha-actinin 
positive hiPSC-CMs (Figure 8B-C). The absence of other biomaterial in 
biomaterial-free 3D printing of cardiac patches, may have facilitated the more rapid 
development of cell-cell contacts containing Cx43 and support more rapid 
propagation of activation through the patches.  
 
The limitations of our study include the short-term culture of our 3D bioprinted 
cardiac patches, the relatively slow conduction velocity of the patches due to 
immaturity of hiPSC-CMs, and the weak mechanical properties of the 3D 
bioprinted patches. The 3D bioprinted patches consisted of a single layer of 
spheroid and the properties of a multi-layer thick patch could be different.  
 
In conclusion, the generation of 3D bioprinted patches created with hiPSC-CMs 
derived from healthy control subjects is promising as a platform for cardiac tissue 
repair. The potential to take a patient’s own cells (skin or peripheral blood), 
reprogram them to hiPSCs then differentiate the hiPSCs to cardiomyocytes is 
fundamental to the field of regenerative medicine. We have demonstrated it is 
feasible to 3D print biomaterial-free cardiac tissue patches using hiPSC-CMs. 





spontaneous beating, electrical integration of component cardiospheres, and 
ventricular myocyte-like cellular electrophysiological properties. This constitutes a 
significant step towards a new generation of stem cell treatment for heart failure for 







Utilization of 3D cardiac patches to deliver cardiac stem cells to the intact 
heart for cardiac repair 
 
4.1.  Introduction 
There are several methods to deliver cardiac stem cells to the heart, for cardiac 
regeneration after myocardial infarction (62). Before the advent of tissue 
engineering, the most common method was cell injection, but this was hampered 
by significant cell loss due to poor cell retention (63). Tissue-engineered 
cardiomyoplasty has been proposed as one of the methods to overcome the 
significant limitation of cardiac stem cell injection (64), as a next-generation 
therapy for cardiac repair (63).  
 
Relevant to the field of tissue engineering in general, significant factors to consider 
in the intelligent design of any tissue, including cardiac tissue, blood vessels (65), 
etc., include cell source (stem cells (66), mature cells, none), the scaffold (natural, 
synthetic, none), and fabrication method, as these will affect the tissue viability, 
paracrine secretion, mechanical integrity and electrical conductivity of the final 
tissue construct. Particularly relevant to cardiac tissue, is electrophysiological 





substrate for arrhythmia development due to conduction delay and block. Scarring 
secondary to low tissue viability of any transplanted 3D cardiac patch can also lead 
to arrhythmia development and sudden cardiac death. Whilst there are already a 
number of studies looking at in vivo implantation of cell spheroids (13), there are 
far more limited studies examining in vivo implantation of 3D cardiac patches. 
 
In this chapter, we look at the clinical translational value of biomaterial-free 3D 
cardiac patches, using 3 different rodent surgical models. 
 
4.2. In vivo implantation of 3D cardiac patches on intact hearts 
Animal procedures were reviewed and approved by the Johns Hopkins University 
Institutional Animal Care and Use Committee and performed in accordance with 
relevant institutional and federal guidelines and regulations for the care and use of 
laboratory animals. Nude rats (NIH RNU sp/sp rats, NTac:NIH-Foxn1rnu, 12 
weeks, female, 165-195 g, Taconic) were anesthetized using isoflurane, intubated 
and mechanically ventilated. A median sternotomy was performed and hemostasis 
was secured. A single cardiac patch was implanted directly onto the heart and 
secured with tissue glue and sutures. The chest was closed under aseptic technique 
and the animals were monitored for recovery from surgery. Animals were sacrificed 





sectioned along the short axis and embedded in O.C.T. compound or paraffin, for 
further histology and immunostaining. 
 
3D bioprinted cardiac patches were implanted onto nude rat hearts (n=4) (Figure 
10A-C) and remain engrafted on rat hearts 1 week after implantation (Figure 10D-
F). Imaging of sections through the patch and native heart tissue reveals viable cells 
in the patch along with erythrocytes (Figure 10D, left, 3 white arrows), suggesting 
vascularization. Collagen staining is also present in the patch (Figure 10E, left). 
Confocal microscopy reveals presence of human nucleic acid (HNA)-positive cells 
in native rat myocardium, suggesting engraftment (Figure 10F, right, white arrow). 
 
Figure 10: In vivo implantation of 3D bioprinted cardiac patches. A: 





anterior surface of the rat heart. B: Explanted heart (cross-section) C: Explanted 
heart (anterior aspect). D: H&E, white arrows indicate presence of erythrocytes. 
Scale bar: 400 µm. E: Masson Trichrome. Scale bar: 400 µm. F: Human Nuclear 
Antigen (HNA) (Magenta), Wheat Germ Agglutinin (WGA) (Green), DAPI (Blue). 
Scale bar: 40 µm. White arrows indicate presence of human cells in native rat 
myocardium. D-F: White dotted line demarcates the cardiac patch (left) from native 
rat myocardium (right).  
 
In vivo implantations of 3D bioprinted cardiac patches onto nude rat hearts 
 (Figure 10) suggested vascularization and engraftment of 3D bioprinted cardiac 
patches, highlighting the promise of biomaterial-free 3D printing of cardiac tissue 
in myocardial regeneration and repair. Long term follow-up and functional analysis 
of the heart will be needed to show the efficacy of these 3D bioprinted cardiac 
patches. Notably, the purpose of the in vivo experiments was to optimize the 
conditions for engraftment and vascularization in vivo, as a proof of principle. 
Future studies involving vascularization, different culture conditions and 
modulation of the tissue with mechanical or electrical stimulation, and implantation 
in a myocardial injury model, amenable to therapeutics, to assess improvement in 






4.3.  In vivo implantation in setting of myocardial infarction 
As an extension of the study in the previous section where 3D bioprinted cardiac 
patches are implanted on intact hearts, this section (Attribution: Yeung et al (4)) 
follows with a functional study in the setting of a surgically created myocardial 
infarction by ligation of the left anterior descending (LAD) coronary artery in the 
same nude rat species. It is noted that the cardiac patch is retained in situ 4 weeks 
after surgery with high viability (Figure 11), decreased scar area (Figure 12), and 
improved vascularization (Figure 13), though there is no significant change in 
cardiac function and left ventricular mass (Figure 14). 
 
Figure 11: In vivo implantation of 3D cardiac patches in rodent LAD ligation 
model: Viability (A) Occlusion of the distal left anterior descending coronary 
artery, suture (green arrow), infarcted area (yellow) (B) Cardiac patch (Blue arrow) 
and omentum patch (yellow arrow) implantation in experiment group (n=6) (C) 





of the cells in rat 4 weeks after surgery, HNA (red), DAPI (blue), D: scale bar  = 
100 um, E: scale bar = 25um (F-G) Evidence of retention of the cells in rat 4 weeks 
after surgery, TropT (green), DAPI (blue), F: scale bar = 100um, G: scale bar =  
25um (H) TUNEL staining of patch 4 weeks after surgery, dead cells are indicated 
by the yellow arrow), scale bar = 100um. (Figure attribution: Yeung et al (4))  
 
 
Figure 12: In vivo implantation of 3D cardiac patches in rodent LAD ligation 
model: Scar area A. Masson Trichrome staining of Sham group. B. Masson 
Trichrome staining of Patch group (Blue = infarcted area) C. Statistical analysis of 
scar area (percentage = blue / total area) (p= 0.048) (Figure attribution: Yeung et 







Figure 13: In vivo implantation of 3D cardiac patches in rodent LAD ligation 
model: Vascularization (A) CD 31 staining of Sham group, scale bar = 100um (B) 
CD31 staining of Patch group, scale bar = 100um (C) Statistical analysis of vessel 
counting (p = 0.001) (Figure attribution: Yeung et al (4))  
 
Figure 14: In vivo implantation of 3D cardiac patches in rodent LAD ligation 
model: Cardiac function (A) Left Ventricular Ejection Fraction, (B) Left 





4.4.  Transmural 3D cardiac patch implantation / “Dor” patch 
Many studies examining cardiac regeneration using tissue engineered cardiac 
patches employ an epicardial approach in part to facilitate the assessment of 
vascularization and engraftment (3, 42, 52). In the previous chapters and sections, 
we have demonstrated the 3D bioprinting of biomaterial-free cardiac patches, made 
using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) 
(3, 14), which exhibit electrical and mechanical integration. These patches were 
subsequently implanted epicardially. The purpose of this study is to evaluate the 
feasibility of performing cardiac repair using reinforced, biomaterial-free 3D 
bioprinted full-thickness cardiac patches, akin to an endoventricular circular patch 
plasty or a Dor procedure (67), pioneered by French cardiac surgeon Vincent Dor 
in 1985, except that instead of a Dacron patch, a reinforced 3D bioprinted cardiac 
patch is used. 
 
Biomaterial-free 3D bioprinted cardiac patches were engineered as previously 
described (3). To withstand ventricular pressures, the 3D bioprinted cardiac patches 
were first mechanically supported between 2 fibrin sheets (12-layers thick 
respectively) created using electrospinning (Figure 15A-B). Full-thickness defects 
were then surgically created in the right ventricles of nude rats (NIH RNU sp/sp 
rats, NTac:NIH-Foxn1rnu, Taconic) (n = 5) (68) (Figure 15C-E). A pursestring 





outpouching of the RV. The RV is then incised. To ensure that a transmural defect 
is created, we made sure there was backflow of blood observed when we loosened 
the pursestring. The 3D bioprinted cardiac patch is then used to fill the defect and 
a PTFE patch is sutured on top of that, to further reinforce the tissue.  
 
One month after implantation, we explanted and sectioned the heart to examine the 
implanted tissue, noting that grossly, the 3D bioprinted cardiac patch remained in 
situ (Figure 15F-H), with extracellular matrix present on Masson Trichrome 
staining (Figure 16A). In addition, there were red blood cells (Figure 16B, black 
arrows) in the 3D bioprinted cardiac patches on hematoxylin and eosin (H&E) 
staining, and CD31 positive blood vessels in the 3D bioprinted patches, consistent 
with vascularization of the graft  (Figure 16C). The surgical RV defect made was 
filled with troponin-, alpha actinin- and human nuclear antigen- (HNA) positive 
cells, indicating the implanted 3D bioprinted patches remained viable (Figure 16D). 
 
Interestingly, we note the presence of DAPI (4',6-diamidino-2-phenylindole) 
positive, HNA negative cells in the 3D bioprinted patches, suggesting the migration 
of rodent cells into the 3D bioprinted patches (Figure 16E, blue arrows). Also, we 
note the presence of HNA positive cells outside the 3D bioprinted patches (Figure 
16E, yellow arrows), indicating the migration of human cells from the 3D 





before explant indicated that the left ventricular ejection fraction was 73% and the 
right ventricular function was preserved.  
 
These findings suggest that the 3D bioprinted patches we implanted contributed to 
tissue replacement of the heart. The surgical transmural defect allowed access to 
RV chamber blood supply to 3D cardiac patches, as compared to epicardial 
implantation, promoting the long-term survival of the patches. 
 
In summary, we demonstrate the feasibility of full-thickness cardiac tissue 
replacement using 3D bioprinted cardiac patches in a novel rat model, with nascent 
vascularization and engraftment of the implanted tissue. The unique combination 
of hiPSC technology and 3D bioprinting technology allows for the possibility of 
patient-specific re-muscularization in patients with ischemic heart disease, using 
patient-specific hiPSC-CMs. The full thickness cardiac repair, in particular, may 
have implications for the treatment of transmural myocardial infarction in the 
future. Further studies evaluating the electrophysiological and mechanical 
integration of the 3D bioprinted patches in vivo, as well as the contractile function 






Figure 15: Schematic diagram of in vivo transmural 3D cardiac patch implantation. 
Panels A, B demonstrates the full-thickness heart repair model (C-D), with cross-
sectional views (E-H) 1-month post-implantation. The black dotted lines indicate 
the cut made for the cross-sectional views. The blue arrow indicates the view for 
cross sectional views G and H, where the 3D cardiac patch is outlined by the white 






Figure 16: Histology and immunofluorescence of transmural 3D cardiac patch. A-
B: Masson Trichrome (A), H&E (B) stains of implanted 3D bioprinted patch. C-E: 
Immunofluorescence of implanted 3D bioprinted patch. C: Green: CD31, D: Green: 
Alpha actinin, E: Green: Troponin, Red: Human nuclear antigen (HNA). All: Blue: 
DAPI. White dotted line indicates the boundaries of implanted 3D bioprinted patch. 
Yellow arrows indicate HNA+ cells, light blue arrows indicate HNA- DAPI+ 
rodent cells. Scale bar: 50 µm. 
 
4.5 3D cardiac patch maturation using chemical factors 
The use of hiPSC-CMs in translational medicine is hampered by the fact that these 
cells do not achieve the full functional maturity of an adult cardiomyocyte (69-71). 





of hiPSC-CMs, one of which is chemical maturation using defined chemical factors 
(72). We created 3D bioprinted cardiac patches made of hiPSC-CMs and 
chemically treated these patches with thyroid hormone, insulin-like growth factor 
1 and dexamethasone (TDI). We have used these CMs to create 3D bioprinted 
patches (Figure 17), and have noted increased sarcomere length (Figure 17A-B), 
increased conduction velocity (Figure 17C) and a more mature cardiomyocyte 
transcriptional profile within the 3D bioprinted cardiac patches  (Figure 17D-F). 
There were no significant differences in ejection fraction after in vivo implantation 
and echocardiography at 1 month of TDI-treated cardiac patches, compared to 
untreated cardiac patches, possibly due to the small size of the implanted cardiac 










Figure 17: Functional changes of 3D bioprinted cardiac patches with TDI treatment. 
(A) Representative confocal microscopy image of cryosectioned a TDI-treated 3D 
bioprinted cardiac patch, stained with DAPI (blue) and alpha-actinin (purple) (B) 
Quantification of sarcomere length in TDI-treated vs untreated 3D bioprinted 
cardiac patch (**** p < 0.0001) (C) TDI treatment improves electrophysiological 
conduction of 3D bioprinted cardiac patches (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001) 
(D-F) TDI treatment leads to a more mature cardiomyocyte transcriptional profile 
within the 3D bioprinted cardiac patches (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001) 







Cardiac disease modelling using 3D spheroids and CRISPR interference 
 
5.1. Introduction 
Calmodulinopathies, caused by mutations in calmodulin (CaM), a ubiquitous Ca2+ 
sensor, can lead to life-threatening cardiac arrhythmias such as long QT syndrome 
(LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT) and 
idiopathic ventricular fibrillation (IVF) (73, 74). For example, a p.D130G-CaM 
amino acid substitution, resulting from a heterozygous c.389 A>G single nucleotide 
substitution in CALM2, has been shown to mediate a decrease in Ca2+/CaM-
dependent inactivation (CDI) of L-type Ca2+ channels (LTCCs), leading to 
prolonged action potentials (APs) and a cellular LQTS phenotype (11). As there are 
3 CALM genes (CALM1, CALM2, CALM3) encoding for the identical CaM protein, 
selective and efficient silencing of CALM2 using a variant of CRISPR/Cas9 
technology, CRISPR interference (75, 76) (CRISPRi), has been shown to lead a 
downregulation of mutant CaM expression and functional rescue of the 
calmodulinopathy phenotype in two-dimensional (2D) monolayers (11). 
 
Meanwhile, three-dimensional (3D) tissue engineering has the potential to 





and retention, prolonged paracrine release and structural support (77). Engineered 
in vitro 3D models of diseases also enable new insights into disease mechanisms 
and provide an opportunity to screen new therapies (78) before clinical application. 
In some circles, this has been termed ‘clinical trials ‘in a dish’ (79). CRISPR/cas9 
technology has been used in 3D organoid models (80, 81) but most of this work 
involves generating reporter cell lines or the introduction of mutations for disease 
modelling.  
 
Combining 3D tissue engineering with powerful programmable nuclease-based 
CRISPR/cas9 genome engineering tools provides an opportunity to study and gain 
further insight into the effects of the added dimensionality as a tissue model of 
cardiac arrhythmia, to uncover disease mechanisms in 3D, such as during human 
organ development. This also represents a further step towards making the 
promising strategy of using CRISPRi for the treatment of congenital LQTS 
resistant to conventional therapy a clinical reality, without permanent alteration to 
the genome. 
 
5.2. Materials and Methods 
Generation of hiPSC-CMs and 2D monolayers 
hiPSC-CMs were generated from a patient with D130G-CALM2-mediated LQTS 





(Figure 18A-B). The hiPSC-CMs were first replated to form confluent 2D 
monolayers and then used to make 3D cardiac tissues. 
 
CRISPR interference and lentiviral creation 
The cloning of lentiviral constructs and screening of gRNA candidates have been 
discussed in a previous publication (11). CRISPRi is employed to selectively 
suppress both wildtype (WT) and mutant CALM2 expression, thus down-regulating 
mutant D130G-CaM expression, reducing disrupting of CDI of LTCCs and 
functionally rescuing the cellular LQTS phenotype. To generate lentiviruses, 
HEK293T cells were separately transfected (Lipofectamine 2000, Invitrogen) with 
packaging plasmids, envelope plasmids and transfer plasmid encoding either an 
enzymatically dead Cas9 fused with suppressor Krüppel-associated box (KRAB), 
a guide RNA (gRNA) backbone or the gRNA targeting CALM2 (both WT and 
mutant). Lenti-X-Concentrator (Clontech Laboratories) was then used to 
concentrate infectious lentiviral vector particles according to the manufacturer’s 
recommendations. 2D and 3D cardiac tissues were then simultaneously transduced 
with 2 lentiviruses, either KRAB/gRNA-CALM2 or KRAB/gRNA-backbone as 






mRNA expression by qualitative PCR (qPCR) 
Cardiomyocytes in 2D and 3D preparations were harvested for qPCR quantification 
to determine CALM1, CALM2 and CALM3 mRNA transcript levels. 
 
Biomaterial-free 3D cardiac spheroid (CS) creation 
The detailed method for creating biomaterial-free 3D cardiac spheroids has been 
discussed in previous papers by our group (2, 82). Briefly, hiPSC-CMs were 
dissociated and co-cultured with dissociated supporting cells, such as human 
cardiac fibroblasts (Sciencell, Carlsbad, CA) and/or human umbilical vein 
endothelial cells (Lonza, Basel, Switzerland), in ultra-low attachment 96-well 
plates. Within 3 days, they form 3D cardiac spheroids (2, 82). 
 
Biomaterial-free 3D bioprinting 
We have also published the method for biomaterial-free 3D bioprinting (19) in 
previous publications by our group (2, 82). Briefly, CSs were picked up by vacuum 
suction using a robotic arm and transferred onto a stainless-steel needle array 
(Cyfuse Biomedical K.K., Tokyo, Japan), where they fuse over another 3 days to 







We have previously described our method for electrophysiological optical mapping 
(82) and applied the same method to both CSs. Briefly, 2D monolayers (Figure 
18A-B, Supplementary Figure A.6), 3D CSs were stained with a voltage sensitive 
dye di-4-ANEPPS and paced at decreasing pacing cycle length until loss of capture. 
Optical recordings were obtained at pacing cycle lengths 2000 ms, 1500 ms, 1000 
ms and 900 ms for 2D  monolayers (Figure 18) and 2000 ms, 1500 ms, 1250ms, 
1000 ms, 800 ms, 600 ms and 400 ms (Figure 20) using a 100 × 100 pixel CMOS 
camera (MiCAM Ultima-L, SciMedia, Costa Mesa, CA) (Figure S6). In addition, 
CSs were placed in a customized chamber to hold the spheroids in position and 
prevent movement artifacts.  
 
Microscopy 
Optical microscopy images were taken using the EVOS XL CORE imaging system. 
Immunofluorescent and transmitted monochrome microscopy images and videos 
were taken using the EVOS FL imaging system. Confocal microscopy images were 







5.3.1. CRISPRi in 2D 
The APD80 shortened by 23% (p=0.02) with pacing at 2000 ms and by 17% 
(p=0.01) at 1500 ms (Figure 18C). There were no statistical differences in APD80 
at pacing cycle lengths 1000 ms and 900 ms. Additionally, the minimal capture 
cycle length decreased to 694 ± 31 ms from 1100 ± 167 ms (p=0.04) (Figure 18D). 
CALM2 mRNA expression decreased significantly to 0.62 ± 0.06 compared to the 
control (p < 0.01), whereas CALM1 expression (1.01 ± 0.07 (p=0.63)) and CALM3 






Figure 18: Cellular LQTS phenotype recapitulated in 2D monolayer using 
CRISPRi. A: D130G-CALM2 2D hiPSC-CM monolayer treated with lentiviruses 
encoding KRAB transcriptional repressor (red fluorescence) and gRNA-CALM2 
(green/cyan fluorescence). Scale bar: 50 µm. B: Confocal microscopy image of a 
D130G-CALM2 2D hiPSC-CM monolayer (Green: α-Actinin, Red: Cx43, Blue: 
DAPI). Scale bar: 25 µm. C: APD80. D: Minimum capture cycle length. E: CALM 
mRNA expression of D130G-CALM2 2D hiPSC-CM monolayers. * indicates p 





5.3.2. 3D Cardiosphere (CS) tissue model of D130G-CALM2-mediated long QT 
syndrome (LQTS) 
We were able to generate 3D CSs using hiPSC-CMs with D130G-CALM2-
mediated LQTS (Figure 19A), record optical action potentials (APs) from them 
(Figure 19B), and use them for biomaterial-free 3D bioprinting (Figure 19C). The 
CSs fused to form an intact beating 3D cardiac patch (Figure 19D-E), that was 
amenable to electrophysiological studies (Figure 19F). Optical action potentials 
were recorded from the 3D cardiac patch (Figure 19G), and demonstrated 
prolonged APs when compared to 3D cardiac patches made from WT hiPSC-CMs 
without disease (82), indicative of 3D tissue electrophysiological LQTS phenotype. 
Figure 19: 3D CSs and 3D bioprinted cardiac patches as 3D tissue models of 
calmodulinopathy. A: 3D CS created using D130G-CALM2 hiPSC-CMs B: Action 
potentials (black trace) recorded by optical mapping. The stimulation artifact is 





bioprinted cardiac patch created using D130G-CALM2 hiPSC-CMs, at the end of 
3D bioprinting (C), at decannulation (D), 2 days after decannulation (E), and at 
electrophysiological optical mapping (F). Scale bar: 1mm. G: Representative 
optical action potential from a 3D cardiac patch. Scale bar: 500 ms. 
 
After transduction with CRISPRi viruses, the 3D CSs exhibited both red and green 
fluorescence (Figure 20A-D), indicating that the KRAB transcriptional suppressor 
and the gRNA were being expressed respectively. CRISPRi shortened action 
potentials (Figure 20E) without significant reduction in minimum pacing cycle 
length (Figure 20F). When quantified, the APD30 was shortened across all pacing 
cycle lengths (2000 ms, 1500 ms, 1250 ms, 1000 ms, 800 ms, 600 ms and 400 ms) 
(Figure 20G) and the APD80 was shortened at pacing cycle lengths 2000 ms, 1500 
ms and 400 ms (Figure 20H). In addition, we noted a reduction in electrical 
alternans at longer pacing cycle lengths in the CRISPRi group, indicating better 








Figure 20: Correction of pathological electrophysiology phenotype in D130G-
CALM2 3D CSs using CRISPRi. A-D: 3D CSs were transduced with lentiviruses 
encoding gRNA-CALM2 (green/cyan fluorescence) and KRAB transcriptional 
repressor (red fluorescence) (A: Transmitted light B/C/D: Green/Red/Merged 
fluorescence). E: Representative action potentials (APs) demonstrating shortening 





cycle length (F), APD30 (G) and APD80 (H) of 3D CSs. A single asterisk indicates 
a p value less than 0.05, double asterisks indicate a p value less than 0.01, triple 
asterisks indicate a p value less than 0.001.  
 
5.4. Discussion 
Most applications of CRISPR in tissue engineering involve correcting mutations in 
2D first, as induced pluripotent stem cells, then using CRISPR-corrected cells for 
tissue engineering (83, 84). While that may be relevant for creating 3D tissue from 
scratch, conceptually that is not as clinically relevant as performing CRISPR 
correction in already-formed intact 3D tissues for the purposes of disease modeling. 
In this present study, to our knowledge, we were the first to demonstrate CRISPRi 
in 3D cardiac tissue. 
 
A change in electrophysiological phenotype was observed after CRISPRi. 3D 
cardiac tissue made using mutant hiPSC-CMs recapitulated LQTS and exhibited 
prolonged optical action potentials (Figure 19) (APD30 255 ms, APD80 444ms), 
compared to 3D cardiac tissue made from hiPSC-CMs without disease (WT) 
(APD30 189 ms, APD80 250ms) (82). 
 
These APDs shortened significantly after CRISPRi knockout of mutant CALM2 





the C-lobe and thus does not produce CDI of LTCCs. The non-inactivating LTCC 
is associated with the persistent depolarizing current that prolongs the APD. 
CRISPRi targeting CALM2 knocks down expression of both WT and mutant 
CaM2, allowing for CaM1 and 3 to compete for binding. These CaMs have retained 
Ca2+ binding, thus mediating CDI of the LTCC, reducing depolarizing current and 
shortening APD. Thus, CRISPRi in 3D CSs functionally rescues the 
calmodulinopathy phenotype and ameliorates pathologically prolonged APDs, 
back to WT. 
 
There are several advantages to using 3D cardiac tissue with an added dimension 
compared to 2D. CSs can be 3D bioprinted to form 3D patches (Figure 19), which 
can subsequently be used for disease modeling if larger 3D cardiac tissue is desired. 
These cardiac patches can also be used for tissue regeneration or creating artificial 
organs. At the same time, CSs can be used for quality control and high throughput 
spheroid drug screen (85), as 3D CSs are more similar to the actual heart muscle 
and thus more clinically relevant, than individual cells in 2D monolayers.  
 
A notable finding is that for CRISPRi to work in 3D tissue, there is no need for 
100% transduction to effect a phenotype change. There is also no need for a 100% 
CALM2 knockdown to effect a phenotype change (Figure 18). This may be due to 





number of CRISPR corrected cells and a critical reduction in existing mutant 
CALM2, there is a resultant electrophysiological phenotype. 
 
5.5. Conclusions 
In this study, 2D cellular LQTS phenotype and 3D tissue LQTS phenotype were 
recapitulated in 2D monolayers and 3D CSs respectively. CRISPRi successfully 
corrects pathologically prolonged cardiac APs, reducing APD80 and APD30, in 
different 3D models and we were able to modulate electrical phenotype in both 3D 
models. The added dimensionality afforded by tissue engineering allows for the 
generation of larger tissues of customized 3D geometry using 3D bioprinting in the 
case of CSs, such as 3D bioprinted cardiac patches, and hence the study of 
correction of congenital LQTS in larger tissues by CRISPRi in 3D. CRISPRi has 
the potential to correct congenital LQTS clinically without permanent alteration to 






3D modeling, 3D virtual reality and applications in cardiovascular medicine 
 
6.1. Introduction 
Virtual reality (VR) is broadly defined as a three-dimensional (3D) simulation of 
the real-world, with the ability for a user to interact directly with the simulation (86, 
87). VR integrates imaging data and user input into a unified graphical output, often 
onto a wearable technology like a headset (86-88). Originally, VR flourished in the 
gaming community, though its use in medicine dates back to the early 1990s (87). 
In its earliest applications to biomedicine, VR was largely applied to the behavioral 
sciences (87), though the advent of “controllers” or sensors that track hand position 
and movements in real time have vastly expanded the ability to interact with the 
virtual space and thus its applications to surgery. Presently, VR is widely used in 
medicine, from stroke rehabilitation (89), to tools for trainees to learn how to 
perform laparoscopic surgery (87, 90). 
 
This interactive rendered 3D environment of VR lends itself well to diseases 
involving complex anatomy, such as congenital heart disease (CHD), complicated 
neurovascular pathology and fetal therapy, as surgical or procedural planning 





and nuanced structural cardiovascular disease. Planning of surgical patch or baffle 
placement, conduit sizing, placement of surgical cannulae or approach (in cases of 
cardiac malposition) can vary by patient. Utility of a 3D modality beyond 
traditional echocardiographic and cross-sectional imaging is currently underscored 
by the rise in 3D printing (91-93). In pediatric cardiology and cardiac surgery, the 
use of VR is emerging. In published literature, VR was used to construct a training 
tool for minimally invasive surgery (94). However, this method lacked the ability 
to interact with the heart, nor could it provide interactive sectioning or 4-chamber 
views. 
 
Beyond surgical planning, VR has also been utilized as a training tool for residents 
and medical students (87, 90). Simulators can incorporate VR to immerse trainees 
in a virtual rendering of a range of different procedures, particularly with 
laparoscopic procedures (87, 90). Previous studies have shown that trainees who 
use these VR simulators in their surgical curriculum face shorter times to 
completion of their learning tasks compared to their counterparts who did not use 
VR (87). The use of VR for surgical planning has been demonstrated in plastic and 
orthopedic surgery (95) wherein surgeons created VR models of their surgical sites 






We present 3 novel uses of VR in CHD, neurovascular pathology and fetal 
medicine, to create virtually rendered high fidelity 3D VR models of the pediatric 
hearts, complex pseudoaneurysm of the internal carotid artery and fetal hearts 
respectively, viewed via a VR headset and controller platform for visualization and 
manipulation.   
 
Additionally, in Section 5 of this chapter, we present a pilot study demonstrating 
the feasibility of 3D bioprinting patient-specific customized biomaterial-free 
cardiac tissue with complex shapes and geometries. The same 3D models, described 
in Sections 2, 3 and 4, and selected parts of the 3D models can be used as the 3D 
template for 3D bioprinting in Section 5. 
 
6.2. Congenital Heart Disease 
In this example, we used high resolution cardiac multidetector computed 
tomography (CT) source data to reconstruct 3D virtual models from two patients: 
one with truncus arteriosus type IV with arch anomalies and another with a large 
ventricular septal defect and congenital diaphragmatic hernia (CDH) causing 
cardiac malposition; these cases were selected to demonstrate common 
periprocedural concerns regarding intra- and extracardiac anatomy. The models, 
controlled in real time by the end user, allow customized and real time immersive 





complex cardiothoracic surgical procedures by assisting in visualization of 
complex spatial anatomy. 
 
6.2.1. Data acquisition and 3D segmentation 
CT of the heart performed following administration of intravenous contrast and was 
exported using Carestream Vue (Rochester, New York, USA). 3D segmentation 
was performed using DICOM to Print (D2P) software (3D Systems, Rock Hill, SC) 
using auto-segmentation and/or thresholding by Hounsfield unit to identify the 
blood pool. A 3D volumetric mask was first created and processed using cutting 
and Boolean subtraction tools. Finally, the 3D mask was converted into a 3D 
surface mesh for VR visualization. Depending on the complexity of the case and 
the experience of the operator, this 3D segmentation process can take less than 30 
minutes, or up to several hours. 
 
6.2.2. VR Visualization 
VR visualization was performed at the Johns Hopkins Carnegie 3D Printing and 
Visualization Facility using a VR platform (Figure 21A), consisting of a VR 
headset with two controllers (HTC Vive, New Taipei City, Taiwan). An area of 12 
feet by 12 feet was designated for VR, and two base stations were used to detect 
the exact spatial location of the VR user and the two controllers. The 3D segmented 





Hill, SC). The VR user can magnify, handle and rotate the entire 3D heart model 
using the left controller (Figure 21B), and section the 3D heart model using the 
right controller acting as a clipping plane for intracardiac or intraluminal viewing 
(Figure 21C-E). To examine the sections at various angles, the VR user can either 
walk around or closer to the 3D heart model visualized in VR, or move, magnify 
and rotate the object using the left controller. Open Broadcaster Software Studio 
(Version 20) was used to capture the VR views (Figure 21B-E, Video B.4). 
 
Figure 21: VR visualization of the heart. (A) Schematic diagram demonstrating the 
VR set-up (B) Various magnifications (C) Persistent Truncus Arteriosus (D-E) 






Figure 22: 3D segmentation of the heart. (A) 3D heart model post-segmentation (B) 
Axial view (C) Coronal view (D) Sagittal view. 
6.2.3. Case 1 
A 2.95 kg baby girl was delivered at full term with a prenatal diagnosis of truncus 
arteriosus, ventricular septal defect (VSD) and aortic arch hypoplasia. The initial 
postnatal echocardiogram on day of life (DOL) 1 demonstrated truncus arteriosus 
type A4 (Van Praagh classification) with ascending aortic arch hypoplasia with 
coarctation versus arch interruption. A CT angiogram (CTA) of the chest was 







The CTA dataset was segmented and processed to create a 3D model which was 
projected into VR. 3D visualization and dynamic manipulations (Figure 21B), live 
sectioning of the 3D heart model to view the VSD as well as the hypoplastic aortic 
arch (Figure 21C-E) was performed successfully in the VR space. 
 
The patient subsequently went to the operating room on the 3rd day of life for 
complete repair with an aortic arch reconstruction using PA homograft patch, patent 
ductus arteriosus division, 10 mm RV-PA conduit (femoral vein graft), patch repair 
of the VSD, and ASD partial closure. The patient made an uneventful recovery. 
The anatomy was accurately represented in the VR space, with improved 
visualization of the arch for surgical planning (Video B.4). 
 
6.2.4. Case 2 
A 5-month-old, 35-week premature infant with a large VSD and right-sided CDH 
was transferred from an outside hospital for surgical management following CDH 
repair and history of extracorporeal membrane oxygenation (ECMO).  
 
Initial transthoracic and transesophageal echocardiograms revealed a large inlet 
type VSD with anterior extension to the paramembranous septum. CT scan 
performed for assessment of cardiac malposition and lung fields revealed extreme 





and left lung hyperinflation. VR model of the patient’s anatomy allowed user 
guided manipulation to envision the VSD margins (including relationships to the 
great vessels) beyond the planes of traditional imaging (Video B.5). Median 
sternotomy at the time of surgery revealed an anteriorly located dilated main 
pulmonary artery with no visualization of the right atrium due to posterior shift. 
Initial venous cannulation was performed in the main pulmonary artery and then 
converted to right atrial cannulation following cardiac decompression. After 
physical leftward rotation of the heart, surgical patch closure of the large VSD via 
a transatrial approach was performed with no residual defects on follow up imaging. 
The child tolerated the procedure well, including postoperative weaning of 
pulmonary antihypertensive medications. The VR model accurately represented 
surgical findings, including VSD visualization in relation to cardiac shift and 
rotation as well as outflow tracts. 
 
6.2.5. Discussion 
The use of VR to generate accurate, patient-specific heart models for immersive 
anatomical assessment in a neonate or young infant is feasible. User defined 
controllers allow for spatial manipulation and segmentation of the heart model in 
real time, suggesting a vital role as a complement to existing imaging modalities in 






The conventional and emerging modalities in cardiothoracic pre-surgical planning 
are computer-based 3D modeling, computer-aided design (CAD) models, and more 
recently, 3D printed models (96, 97). We believe that our described method of pre-
surgical planning using interactive VR with controllers provides several advantages 
in the growing paradigms of pre-operative planning. 
 
VR vs. 2D Visualizations of 3D Heart Models (from CT, MRI or 3D Ultrasound) 
Modalities such as CT, magnetic resonance imaging (MRI) and 3D ultrasound are 
increasingly used in CHD for 3D spatial demonstration, however these remain 
limited by 2D monitor-based visualization of 3D models, limited realism and depth 
perception, as well as inability for user specific manipulation. In VR, the user can 
move themselves or move the model, allowing for dynamic inspection of the 
patient’s anatomy for visualization from a “surgeon’s perspective” while 
preserving the perception of a 3D space. The surgeon’s understanding is also 
increased by displaying views with VR that cannot be achieved in the OR such as 
the proximity to “unseen” surrounding structures. Additionally, the adjustable 
cutting planes allow for visualization of how surgical tools might interact with the 
anatomy, aiding preparedness for the procedure.  
 
VR also offers an advantage over the current pre-surgical or interventional planning 





by the non-invasive imaging pediatric cardiologist to surgeons, interventionalists, 
cardiologists, anesthesiologists and other relevant providers, including trainees. By 
shared viewing and real time manipulation of the anatomy by both the cardiologist 
and surgeons, a better dialogue and shared mental model may be achieved. This 
shared viewing experience can also be potentially projected into multiple VR 
screens, now easily available in mass-market mobile phones with cost-effective 
Do-it-yourself (DIY) cardboard kits, as a teaching tool, and increasingly affordable 
mixed reality headsets with higher viewing resolution, for actual operative 
planning. Data security raises important practical concerns. 
 
VR vs. 3D Printed Heart Models  
Like 3D printed heart models, VR technology allows for the physical manipulation 
of complex anatomy, while offering depth perception and visualization with a 
binocular field of view. VR does offer some specific advantages over rapid 
prototyping. Visualization of anatomy is malleable, not limited to a single cutting 
plane or viewing window on a physical model, since 3D masks and meshes can be 
edited and re-visualized using VR as often as necessary. Planning and expertise for 
material support apparatus for fine structures is precluded on a virtual model. 
Finally, the resolution of the VR heart models is not limited to the capabilities of a 
printer, unlike 3D printed heart models. Using VR, a model can be used to 





being able to be magnified or minimized to a wide range of sizes to the operators’ 
preference. The use of high-resolution source data is critical for both modalities and 
fastidious attention to accurate segmentation allows reconstruction of all relevant 
structures. A preclinical translational study has shown that with sufficiently high 
image resolution initially, images based on VR can be fused with the intraoperative 
imaging environment with good alignment and may even guide intraoperative 
interventions (98).VR models control costs and upkeep necessary for 3D printing 
(99), making VR a cost-effective alternative in the long term. Although VR incurs 
start-up costs such as the purchase of VR equipment (VR headsets, hardware, 
software, appropriate viewing monitors, etc.), arguably there are comparable start-
up expenditures involved for 3D printing as well, such as start-up costs to purchase 
3D printing equipment and materials, or fees to use a 3D printing facility. The 
actual costs vary widely, depending on the quality of the VR equipment and 3D 
printing equipment/facility. There are equivalent personnel costs for 3D 
segmentation by specialized technicians for both 3D printing and VR, as 3D 
segmentation is common to both technologies. However, after initial costs, VR may 
reduce costs compared to 3D printing, as there is no need to regularly purchase 3D 
printing material or incur costs pay to use a 3D printing facility. Also, magnification 
in VR allows for clearer visualization of internal and external structures, which may 
be otherwise expensive to print. Proper storage and disposal of 3D printed models 





fiscally sustainable form of pre-surgical planning. While digital imaging and 
communications in medicine (DICOM) storage of VR models is not an 
insignificant concern, it also offers the advantage of inclusion into the patient’s 
medical record for future reference as well.  
 
Limitations 
Use of our software for VR relies on CT, MRI or cone beam computed tomography 
(CBCT) data to construct the VR model. Echocardiography, the standard imaging 
modality used for pediatric patients, was not used for VR, however this may be an 
emerging technology. The incremental use of 3D echocardiography in congenital 
heart disease and its burgeoning application to 3D printing (100-102) will likely 
extend to VR as well. Current limitations to the use of 3D echocardiography for 
rapid prototyping are the lack of standardized image acquisition protocols, and 
variability in image processing software capabilities and optimization of the 3D 
dataset, for accurate and convenient segmentation. 
 
An alternative workflow solution is use of a third-party product that allows for 
accurate STL generation from source 3D echocardiographic data for importing of 
STL models for VR interaction. Also, upgraded 3D echocardiography machines 
and updated 3D echocardiography software may potentially allow for the export of 





provide a limitation to the use of VR for pre-surgical planning in some pediatric 
cases. However, when imaging is available, whether in adult or pediatric 
cardiothoracic cases, VR may contribute potently to pre-surgical planning.  
 
In addition, while VR may be relatively cheaper for multiple 3D segmentations and 
multiple VR 3D visualizations, a single 3D printed model offers the convenience 
of portability, without the need for a headset and other specialized equipment. This 
is important if the model will be referred to in the OR setting. While video 
recordings of VR (Videos B.4, B.5) can also be conveniently saved and projected 
onto existing OR computer screens with relative ease, the interactivity with the 
model is lost in pre-recorded videos. A 3D print can be shared for device planning 
as well. Other limitations include VR equipment and software start-up costs, the 
lack of existing standards and insufficient evidence so far to support value (the latter 
two may reflect the limitations of new technology in general). Ultimately, some 
products allow a shared workflow for DICOM segmentation of both visualization 
techniques and use of VR may complement the application of 3D printing. 
 
6.3. Vascular Disease 
In this example, we use the same novel VR visualization system for vascular 





management of aneurysms. This system has been developed as an adjunct to 
standard 2D representations.  
 
6.3.1. Data acquisition  
A 3D time-of-flight MR angiogram was acquired through the cervical arteries 
followed by a 3D long axis high-resolution proton density (PD) weighted black 
blood MRI sequence. After a precontrast mask sequence was acquired, 0.1 mmol 
per kilogram of a gadolinium-based contrast agent was administered and a 3D 
contrast-enhanced MR angiogram was acquired during arterial and venous phases. 
3D and long and short axis 2D high-resolution black blood MRI sequences were 
acquired postcontrast, including high-resolution 3D black blood MRI images in 
coronal and sagittal orientations with T1-weighting.  Maximum-intensity 
projection (MIP) images were reconstructed from the MRA data sets.  
 
6.3.2. 3D Segmentation and Interactive Virtual Reality System 
Similar to the previous section, the Digital Imaging and Communications in 
Medicine (DICOM) dataset was imported into DICOM to Print (D2P) software (3D 
Systems, Rock Hill, SC) with automatic segmentation and vascular segmentation 
modules, which were used to identify bilateral carotid vasculature (Figure 23A-C) 
from their origins in the aorta, to create a preliminary 3D mask. Of note, this is not 





careful review of individual slices to identify smaller vessels and to remove 
structures that were not of interest. A 3D mesh with opaque (Figure 23D) and 
translucent views (Figure 23E) was created from the 3D mask. The same VR 
system (HTC Vive, New Taipei City, Taiwan) was used by neurointerventionalists 
(Figure 21A, Figure 23F, Video B.6) to visualize and interact with a 3D model of 
the right carotid pseudoaneurysm in VR. Two base stations were installed to detect 
the location of the operator wearing the VR headset, as well as the two 
accompanying VR handheld controllers. The 3D mesh (Figure 23D) was then 
displayed inside the VR headset (Figure 23G) using D2P software (3D Systems, 
Rock Hill, SC). One of the handheld controllers was designated for rotation, 
magnification and handling of the model, and another was designated to act as a 
clipping plane (Figure 23H) to examine cross-sectional views of the right carotid 
pseudoaneurysm. For visualization, the operator had the option to move himself or 
herself physically relative to the displayed object or move the position of the 3D 
model using the controllers. Two board certified neuroradiologists, with 11 and 6 
years of neuroimaging interpretation experience respectively, used the VR 
projection system to evaluate MRI images of a complex pseudoaneurysm of the 
right internal carotid artery. Both operators filled in a questionnaire detailing their 






Figure 23: VR projection of right carotid pseudoaneurysm: (A) Axial view, (B) 
Sagittal view, (C) Coronal view, (D) Opaque view, (E) Translucent view, (F) 
Interventional neuroradiologist using VR, (G) VR projection, (H) VR projection 







The segmented DICOM files from 3D angiographic imaging data was successfully 
loaded into the D2P software VR module and an evaluation was successfully 
performed in the VR environment.  
 
MRA demonstrated a complex, partially thrombosed, large pseudoaneurysm 
involving the mid to distal right cervical ICA. The proximal ICA supplying the 
pseudoaneurysm was moderately to severely narrowed as it was compressed by 
thrombus at the level of the right lateral mass of C2. The lumen subsequently 
expanded within the thrombus, filling the inferior aspect of the pseudoaneurysm. 
There was moderate to severe flattening of the ICA after it exited the 
pseudoaneurysm with the vessel compressed up against the right mastoid process 
by the pseudoaneurysm below. 
 
Visualization Modes: 
Currently angiographic 3D mesh data could be visualized as both opaque ((Figure 
23D) and translucent (Figure 23E) representations, however, only the opaque 






Opaque display: This mode was especially useful when evaluating surface 
morphological parameters such as lobulations, daughter sacs, and surface 
irregularities. 
 
Translucent projection: This mode proved particularly helpful to evaluate inflow 




Key anatomical landmarks were reliably visualized using both conventional opaque 
and translucent projection modes (Figure 23A-E) and the virtual environment 
(Figure 23G-H). The operators were able to visualize outflow and inflow tracts and 
rotate the model to obtain a working view that clearly outlined a potential trajectory 
for endovascular device deployment.  
 
Aneurysm size, shape, contour and morphology were all adequately assessed with 
all details defined on conventional imaging resolved in the VR environment. As 
more potential views of the aneurysm could be assessed, there were a greater 
number of potential options for evaluation of size, shape and volume. A true 
aneurysm volume could be defined (as opposed to an inferred volume based on 2D 





sacs, and surface irregularities were all apparent to the operator. The level of 
granularity of assessment was at least as high as any depiction on conventional 
surface rendered radiographic imaging. 
 
Procedural duration: 
The operators were both able to complete an entire pre-procedural radiographic 
work-up in under 10 minutes, including a period of approximately 3 minutes to 
learn to operate the head mounted VR display and the hand controllers.  
 
Operator preferences and observations: 
There was a relatively short learning curve in becoming familiar with the device’s 
controls, getting used to the presence of the VR headset and controllers and being 
inside the virtual environment. After an adjustment period, the operators found the 
VR headset and controllers unobtrusive and were able to wear them throughout the 
procedure without discomfort. The operator did not report any nausea, vertigo or 
disorientation during or after using the VR device.  
 
6.3.4. Discussion 
The past decade has seen a concurrent increase in the use of advanced radiological 
imaging technologies and minimally invasive intervention in the clinical setting 





visualization of 3D data representations on a flat panel screen. This case 
demonstrates that current 3D visualization technology allows us to move beyond 
traditional radiographic monitors to an interactive 3D virtual reality (VR) 
experience with multiple advantages for patient care, clinical training and medical 
education.  
 
With VR visualization, the clinician is able to literally immerse themselves into the 
patient’s anatomy and can garner an unprecedented real-time understanding of 
micro- and macro-anatomy. In the case of the large pseudoaneurysm illustrated in 
this report, the operators were able to visualize vascular inflow and outflow tracts 
optimally, as well as infer areas which represented intra-lesional thrombus.  This 
allows for better pre-procedural planning and consideration of various 
interventional options, including reconstructive options such as placement of stents, 
or deconstructive options such as vessel sacrifice.  
 
The operators were particularly impressed by the level of detail that could be 
defined about surface morphological parameters, such as of lobulations, daughter 
sacs, and surface irregularities, especially since aneurysm wall irregularity and 






The operators found the system intuitive (as demonstrated by the short time period 
required to learn to operate the system). They were also able to quickly adapt to the 
idea of being immersed in the displayed environment. The VR system uses a high 
definition display with precise low-latency constellation head tracking capabilities 
and relies on natural sensorimotor contingencies to perceive interaction with 
realistic anatomy.  The virtual controllers are also of the same dimensions and 
shape in the virtual environment, resulting in two identical familiar objects in the 
virtual environment for the operators to quickly adapt to. The operator is able to 
visualize structures from multiple viewpoints within any portion of the room by 
moving their own body in a set of instinctively intuitive ways – they can turn their 
head, move their eyes, bend down, look under, look over and look around to study 
the object from any angle.  
 
The operator is also provided with a realistic representation of the handheld 
controller interface with a six degrees-of-freedom and can therefore perform 
movements (such as picking up virtual objects) that are more intuitive than using a 
keyboard or mouse. This ability to orient the virtual object in any plane and place 
it in the visual field using handheld controllers allows the operator to mimic 
potential patient positioning for surgery or intervention. The observer can reach out, 
touch, push, pull and perform these or a subset of these actions simultaneously to 





images acquired in one position and interpreted in another (such as evaluating 
anatomic structures in a simulated erect position where the images may have been 
acquired supine or prone).  Preliminary results of the use of this technology suggest 
a high level of user comfort, ease of use and adaptation to these types of hand-held 
controllers (110). Through these mechanisms, VR is able to provide an experience 
that gives rise to an illusory sense of place (“place illusion”) and an illusory sense 
of reality (“plausibility”) (111, 112). 
 
In addition to object navigation and orientation, the operator can also utilize one of 
the controllers as a cutting plane to remove extraneous information from the field 
of view. This cutting plane is again more intuitive and easier to use than software 
applications in traditional radiology software visualization packages. Such 
packages often require technical knowledge in order to crop images and are often 
cumbersome, requiring multiple steps icons and other user interface shortcuts. The 
HTC Vive has a controller for increasing or reducing the size of images, which can 
easily be manipulated, with the use of the operator’s thumb. This can therefore be 
achieved without having to distract from any of the other tasks the operator may be 
performing (such as cropping the image).  
 
The literature has reported that observers uniformly remark on the realism of the 





conventional display screens in that it reproduces the way in which light rays hit 
each eye (114). This has the effect of bringing the virtual object much closer to the 
operator’s eyes and rendering it in a more detailed fashion than would be feasible 
in a typical diagnostic radiology setting. VR can assist radiological evaluation by 
considerably diminishing or cancelling out the effects of unsuitable ambient 
conditions. The viewer is shielded from the outside environment, limiting or 
removing the effects of suboptimal background lighting, reflective glare, reducing 
visual distractions and focusing on the subject matter at hand (115). 
 
Beyond the patient care setting, VR technology enables the demonstration of 3D 
anatomic relationships efficiently and clearly and its use for such educational 
purposes is expected to increase considerably in the coming years. In an academic 
conference and peer-teaching setting, VR allows interactive presentations of 
anatomy and real-time demonstrations to colleagues much like performing an open 
neurosurgical procedure (without the requirement for the trainee to be in the 
interventional suite).   
 
There are many potential future directions of applications of VR visualization to 
vascular neuroradiology and neurointervention that are being explored. Our group 
is currently working on integrating vessel wall imaging information into a virtual 





segmentation and co-registration may facilitate merging multiple imaging 
modalities (such as MRI, CT and Nuclear medicine studies) to create a composite 
virtual object that can detail optimal information about multiple tissues and 
anatomic structures. Such advances may also allow for the creation of virtual 
objects representing endovascular devices, which could be sized in a virtual 
environment prior to being used in a procedure. This would allow the operator to 
compare the potential merits of different device constructs in an individual case.  
 
6.4. Fetal Therapy 
Fetal congenital abnormalities, of which cardiac abnormalities contribute up to 50 
percent, is the leading cause of infant death (116-118). Thus, early detection of 
cardiac abnormalities is crucial since they often require complex surgeries and thus 
referral to tertiary care centers that can improve the chance of survival for babies 
with serious heart defects (119). Detection of these cardiac abnormalities can be 
done through a variety of methods, including fetal cardiac ultrasound between 18 
and 22 weeks. Transvaginal scan can also be performed earlier, and fetal 
echocardiography can be performed in high-risk cases such as with hydrops (120, 
121). The detection of fetal abnormalities can alter the pregnancy plan, including 
planning for therapy, mode of delivery, referral for surgery, or termination (122). 





abnormalities will be beneficial to improve outcomes, preparation, and 
interventions after birth. 
  
Several of these fetal cardiac abnormalities are critically in need of timely 
intrauterine intervention to promote survival. Currently, candidates for these 
interventions are limited, but include aortic valve stenosis with evolving 
hypoplastic left heart syndrome and a fetal heart block (123). In fact, a study 
showed that surgery after prenatal diagnosis of hypoplastic left heart syndrome 
improved survival compared to patients diagnosed after birth (124). Current 
limiting factors for the development of new interventions are technological 
challenges and poor candidate selection. There is a need for a guideline for 
standardized diagnosis of fetal congenital heart diseases and for a multidisciplinary 
team for interventional diagnosis (125). Thus, the introduction of VR to visualize 
models of the heart in a virtual 3D space can offer significant advantages in this 
area. 
  
VR in medicine and its capability to produce an interactive environment with the 
ability to control objects in an immersive environment (126) can have beneficial 
effects in visualizing fetal congenital abnormalities and preparing for in utero 









We have discussed our system of segmenting 2D computed tomography (CT) or 
magnetic resonance imaging (MRI) image data to produce 3D models, which are 
then projected into VR, in previous sections (8, 9). As CT scans are contraindicated 
in pregnancy and MRI does not have the necessary temporal resolution for 
acquisition of image data suitable for 3D segmentation, we opted to use 3D 
ultrasound data. The first step to obtain data using 3D ultrasounds is to define the 
region of interest and acquire the details of the cardiac anatomy. At the same time, 
optimize the setting and the imaging window to get the best resolution image and 
to avoid any artifacts. In our study, the 3D ultrasound volumes of a normal fetal 
heart and a fetus with right-sided aortic arch were acquired, post-processed and 
exported as 3D models during cardiac systole. These virtual files were then 
imported into a VR setup (DICOM to PRINT, 3D Systems, Rock Hill, SC) with 
controller-based interactive capability (Vive, HTC, Taipei). Two board certified 
fetal surgeons (AB, JM) and a fetal therapy fellow (MF) tested the VR system and 







3D ultrasound data was successfully converted into 3D models of the fetal heart. In 
VR, these models can be dynamically manipulated in any size in VR as desired by 
the operator, using VR controllers. The handling and movement of 3D models in 
VR is akin to that of 3D objects in reality, with high visual resolution afforded by 
the VR headset similar to 3D objects in reality. The 3D cardiac VR models can be 
sectioned at different angles to allow the identification of fetal structures (Figure 
24). The angles of sectioning are not limited to the typical x-y-z Cartesian planes 
as seen in traditional 2D visualizations.  
 
Figure 24: A-D: Normal fetal aortic arch (A) with cross-sectional views (B-D). E-







In this study, 3D models were derived from 3D ultrasound volumes of the fetal 
heart. The advantage of this approach is that the user can manipulate and handle the 
heart models in virtual space easily. Not only that, the VR models of the fetal hearts 
can also be sectioned at all angles, which cannot be accomplished in 2D 
visualizations often presented by other imaging models. VR offers the advantage 
of performing real-time sectioning and allows unlimited magnification, which is 
not possible with 3D prints, while reducing material costs associated with 3D 
printing. 
  
Over the past decade, researchers have adopted VR for a variety of medical 
purposes, including behavioral treatment for specific phobias (127) and for stroke 
rehabilitation (128). VR is especially useful for these situations since it provides an 
opportunity for patients to immerse in new treatments and therapy tasks that cannot 
be provided in a clinical setting or are often more enjoyable than ones in a clinic 
(128). For the application of fetal heart imaging, the 3D manipulation capabilities 
distinguish VR from its imaging counterparts, which are restricted to visualizing an 
object on the computer screen and often in 2D. There are also many mobile 
applications that allow users to visualize digitized models of the heart, but these are 
generally not personalized models of the heart, and they also have limited 





screen with limited dimensions using mouse clicks. VR allows operators the ability 
to manipulate objects with their own two hands, and thus with greater dexterity. 
  
VR can be useful for detecting anomalies and educating patients. There are 
currently a variety of ways to image the fetal heart during pregnancy, and these are 
often capable of detecting congenital heart defects in utero. Fetal echocardiography 
can detect most cardiac defects and is a routine antenatal screening method (129). 
On the other hand, ultrasonography is an imaging modality that is low in cost, high 
in safety and patient comfort and experience. Fetal MRI is helpful to define a 
prognosis for fetal central nervous system anomalies (129). VR provide an 
additional modality for operators to visualize CHDs that can supplement current 
methods to detect and diagnose CHDs. However, unlike the other methods, VR 
provides a patient-friendly viewing experience that is easier to understand; it would 
be easier for operators to explain and educate patients using a 3D reconstruction of 
their child’s heart.   
 
Furthermore, VR can enhance the current technologies available for presurgical 
planning. One problem in the status quo is that there is a high number of medical 
errors attributed to limited training and planning opportunities and having rich 3D 
models of hearts would allow medical professionals to train and prepare for their 





interventional cardiology, it is important to develop new methods to enhance our 
ability to perform these methods (130). For example, VR can be used to identify 
lesions or be used as a method for simulated training. Similar to how VR has been 
studied to assist with presurgical planning for cerebral gliomas, hepatic surgery, 
orthognathic surgery or minimally invasive neurosurgery (131-135), this new 
technology allows for presurgical planning in utero. 
  
Despite the many advantages of VR in visualizing the fetal heart, there are several 
limitations to using VR. One main limitation is the cost involved in setting up such 
a system, as it involves the initial purchase and setup of expensive computer 
equipment and headwear required to visualize the images. The additional labor cost 
of segmentation and rental of equipment for patient use can be a burden for patients 
who would benefit from this technology, both in terms of cost and ease of use. 
Furthermore, at this time, these VR projections are not portable as the headset has 
to be connected to a computer central processing unit (CPU), which may be 
problematic for settings in the clinic and operating room where individuals may 
want to easily communicate and transfer VR images. We are aware of attempts to 
miniaturize VR, driven mainly by computer gamers, so that the CPU is housed in a 
backpack with a battery pack, which may eliminate this problem in the foreseeable 
future. Also, at this time, only one person can view and handle the VR object. It is 





but that corresponding video projection (Video B.7) will not have the VR effect as 
experienced by the operator handling the object. It may be possible to duplicate the 
VR projection onto another VR headset, but current technology does not allow for 
different users to manipulate the same object at the same time, unlike in reality, 
where a 3D printed object can be passed around and viewed at the same time from 
different angles by different operators. This is because viewing and using VR is 
restricted to headsets and corresponding videos.  
 
6.5. Complex 3D bioprinted cardiac tissue 
In this section, we demonstrate the feasibility of 3D bioprinting complex cardiac 
tissue. Firstly, the complex 3D design (Figure 25A) is broken down into multiple 
2D slices (Figure 25B-D), and bioprinted by assembling spheroids on a needle array 
(Figure 25E-I). The complex 3D bioprinted cardiac tissue is then transferred into 
cell media for further cell culture (Figure 25J-K). After 3 days, the spheroids fuse 
(Figure 25L) to form an intact tissue that is decannulated and removed from the 







Figure 25: A: 3D design for intended 3D bioprint. B-D: Representative 2D slices 
of the intended 3D bioprint. E: Complex 3D bioprinted cardiac tissue. F-I: Aerial 
view of complex 3D bioprinted cardiac tissue, inset (G, I). J-K: Side view of 
complex 3D bioprinted cardiac tissue after transfer into appropriate cell media. L: 
Side view of complex 3D bioprinted cardiac tissue 3 days after cell culture. M-N: 






We present our preliminary use of virtual reality in cases of CHD, neurovascular 
pathology and fetal medicine to illustrate the feasibility and potential advantages of 
this new technology, as well as a pilot study demonstrating the feasibility of 3D 
bioprinting patient-specific customized biomaterial-free cardiac tissue (a patient-
specific 3D cardiac model or part of a 3D cardiac model) with complex shapes and 
geometries. 
 
In the case of CHD, the selected cases demonstrate complex intra and extracardiac 
spatial relationships commonly encountered in structural heart disease and were 
accurate representations of intraoperative findings. Specific advantages of VR in 
complex CHD include: 1. An immersive environment preserving 3D viewing 
similar to the operative environment; 2. Customizable visualization in any arbitrary 
plane by the end user in a preserved 3D viewing space; 3. Cost containment and 
storage over 3D physical prints, in some cases. Shared viewership may provide the 
additional important benefit of enhanced trainee education and improved 
communication amongst providers. While we have represented our use of this 
technology on two infants, application of VR naturally extends to the growing 
population of adult congenital patients with complex, sometimes traditional 
surgical repairs of previous eras, and need for future interventions. For both infants 





interventions as well as expected outcomes in a tangible format. Future studies are 
necessary to assess the impact on surgical decision making, training and cost 
containment. 
 
In the case of neurovascular pathology, we demonstrate the feasibility of using VR 
as an adjunct to conventional imaging technologies and physical displays for the 
pre-therapeutic evaluation of neurovascular pathology. This novel visualization 
approach may represent a valuable adjunct tool for neurovascular pathology in 
general, notably when subtle nuances in aneurysm morphology and angio-
architecture are critical for therapeutic decision making. 
 
In the cases of fetal medicine, we present a novel use of VR for the interactive 
visualization of normal and abnormal fetal cardiac anatomy, using prenatal 3D 
ultrasound data. Advantages of this system include the ability to easily visualize a 
fetal heart with unlimited magnification and from unlimited angles, compared to 
other imaging modalities of the fetal heart, as well as to provide an assistance tool 
for presurgical planning. However, several limitations need to be addressed 
including the limited image sharing capabilities. We expect that future 
developments, both in the medical field and elsewhere, will continue to address 






Executive summary, Conclusions  
 
7.1. Executive Summary 
In this PhD thesis dissertation: 
• We demonstrated biomaterial-free methods to create patient-specific 3D 
cardiac spheroids and 3D bioprinted cardiac patches using hiPSC-CMs.  
• The 3D bioprinted cardiac tissue demonstrate mechanical and electrical 
integration of component cardiac spheroids, with spontaneous beating in 
vitro. 
• 3D bioprinted cardiac tissue demonstrate promising in vivo biological 
function when implanted in rodent models. 
• Biomaterial-free cardiac tissue made using hiPSC-CMs generated from a 
patient with an inherited calmodulinopathy, resulting in congenital long QT 
syndrome, recapitulate disease phenotype with prolonged cardiac action 
potentials 
• CRISPR interference successfully corrects this disease phenotype, 
shortening the prolonged cardiac action potentials significantly. 
• 3D models of cardiovascular structures can be projected into interactive VR 





• Biomaterial-free 3D bioprinting can be used for complex 3D designs, 
including multilayered structures. 
 
7.2. Broader Lessons  
The dissertation demonstrates the feasibility of biomaterial-free 3D bioprinting in 
the field of cardiology and cardiac surgery. It demonstrates the uses of biomaterial-
free 3D cardiac tissue for cardiac regeneration and cardiac disease modelling. It 
also shows how complex patient-specific anatomy can be converted into 3D model, 
and projected into interactive VR for congenital heart disease, neurovascular 
pathology and fetal medicine. These complex patient-specific anatomical structures 
can be 3D bioprinted without biomaterial. 
 
7.3. Future Work  
Future work can focus on, extending the in vivo application of these cardiac tissues 
to larger animal models, e.g. sheep, pig, dog, to gather more preclinical data. 
CRISPR interference can be used to correct other diseases other than the CALM2 
mutation demonstrated in this study. CRISPR correction may also be performed 







A.1. hiPSC-CM 2D monolayer quality   
 
hiPSC-CM 2D monolayer quality by spontaneous beating phenotype and optical 
electrical mapping. A-D : Optical microscopy of 2D CM monolayer as a connected 
beating sheet (A), with connected beating areas (B), isolated beating areas (C) and 
that are not beating (D). Scale bar: 500 µm. E: Isochronal activation map of hiPSC-







A.2. Cardiosphere optimization studies  
A-C: IPSCs (100%) do not form 
spheroids after 24 hours (B) and 48 
hours (C) in ultra-low attachment 96-
well plates (Top row: 4x 
magnification, Middle row: 10x 
magnification Bottom row: 20x 
magnification). Instead a soft gel-like 
cell aggregate, that is easily 
disrupted, forms within 24 hours. D-
F: hiPSC-CMs (100%) do not form 
spheroids after 24 hours (B) and 48 
hours (C) in ultra-low attachment 96-
well plates (Top row: 4x 
magnification, Middle row: 10x 
magnification Bottom row: 20x 
magnification). Instead, multiple 
small scattered spheroids form within 





A.3. Additional images of 3D bioprinted cardiac patches  
 
A: Top view of a 3D bioprinted cardiac patch (white arrow) on a 26 x 26 needle 
array. Scale bar: 1 mm. B: Top view of a 3D bioprinted cardiac patch (white arrow) 
on a 26 x 26 needle array. Scale bar: 10 mm. C: Side view of a 3D bioprinted cardiac 
patch (white arrow) on a 26 x 26 needle array. Scale bar: 10 mm. D: Side view of 
a 3D bioprinted cardiac patch (black arrow) on a 9 x 9 needle array. Scale bar: 4 
mm. E: Side view of a 3D bioprinted cardiac patch (white arrow) on a 26 x 26 







A.4. Cardiosphere cell viability  
 
Cell viability assessment by confocal imaging of the mid-section of a cardiosphere 
stained with cytotoxicity kit (live cells green, dead cells red). Scale bar: 100 µm 
Note: The cell viability of the cardiospheres (33,000 cells per cardiosphere, 
CM:FB:EC ratio 70:15:15) assessed by 3D cell viability ATP assay was 93.3%. 
The standard curve was generated by using cell mixtures consisting of 104, 105, 






A.5. Cell distribution in 3D bioprinted cardiac tissue  
 
Number of nuclei per HPF (40x) of 3D bioprinted cardiac patch in the periphery: 
88.5 ± 3.1 nuclei/HPF (n=4) vs. center: 92.3 ± 3.5 nuclei/HPF (n=4) (Number of 






A.6. Electrophysiological studies of calmodulinopathic 2D monolayers 
 









B.1. Biomaterial-free 3D bioprinting instructional video with narration  
Journal of Visualized Experiments https://www.jove.com/video/55438/creation-
cardiac-tissue-exhibiting-mechanical-integration-spheroids (2) 
B.2. Video microscopy of 2D CM monolayers. 
A: Connected beating sheet (Grade A). 
B: Connected beating areas (Grade B). 
C: Isolated beating areas (Grade C). 
D: Not beating (Grade D). 
https://static-content.springer.com/esm/art%3A10.1038%2Fs41598-017-05018-
4/MediaObjects/41598_2017_5018_MOESM3_ESM.mov (3) 
B.3. Representative optical mapping video of 3D bioprinted cardiac patch 
(CM:FB:EC 45:40:15). Top: 3D bioprinted cardiac patch. Middle: Action potential 
recording at the magenta dot in the 3D bioprinted cardiac patch. Bottom: Pacing 
stimulus (Pacing cycle length 2000 ms). Scale bar: 500 µm. https://static-
content.springer.com/esm/art%3A10.1038%2Fs41598-017-05018-
4/MediaObjects/41598_2017_5018_MOESM2_ESM.mov (3) 







B.5. VR (Congenital Heart Disease Case 2) 
https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Fchd
.12587&file=chd12587-sup-0002-suppinfo2.mp4 (8) 
B.6. VR (Vascular Disease): Visualization of the right carotid pseudoaneurysm 
using an interactive VR system (9) 







1. Ong CS, Pitaktong I, Hibino N. Principles of spheroid preparation for 
creation of 3d cardiac tissue using biomaterial-free bioprinting. In: Crook J, ed. 3-
d bioprinting: Principles & protocols: Springer Nature;2019. 
2. Ong CS, Fukunishi T, Nashed A et al. Creation of cardiac tissue exhibiting 
mechanical integration of spheroids using 3d bioprinting. J Vis Exp 2017(125). 
3. Ong CS, Fukunishi T, Zhang H et al. Biomaterial-free three-dimensional 
bioprinting of cardiac tissue using human induced pluripotent stem cell derived 
cardiomyocytes. Scientific Reports 2017. 
4. Yeung E, Fukunishi T, Bai Y et al. 3d printed cardiac patch augments 
angiogenesis and reduces scar tissue formation in vivo. Southern Thoracic Surgical 
Association 65th Annual Meeting. Amelia Island, FL;2018. 
5. Ong CS, Fukunishi T, Pitaktong I et al. Cardiac remuscularization using 3d 
bioprinted cardiac patches. Circulation 2017;136(Suppl 1):A15589-A15589. 
6. Ong CS, Fukunishi T, Zhang H et al. Improvement of electrophysiological 
and morphological characteristics of 3d bioprinted human induced pluripotent stem 
cell-derived cardiac patches by defined factors. Congenital Heart Surgeons' Society 





7. Ong CS, Huang CY, Han J et al. Crispr interference to correct diseased 2d 
and 3d hipsc-cms with calmodulinopathies. Circulation 2018;138(Suppl 
1):A11569-A11569. 
8. Ong CS, Krishnan A, Huang CY et al. Role of virtual reality in congenital 
heart disease. Congenital heart disease 2018;13(3):357-361. 
9. Ong CS, Deib G, Yesantharao P et al. Virtual reality in neurointervention. 
Journal of vascular and interventional neurology 2018;10(1):17-22. 
10. Ong C, Faden M, Baschat AA, Garcia J, Miller JL. Oc05.03: Virtual reality 
projection of fetal cardiac anomalies from three-dimensional prenatal ultrasound 
data. Ultrasound in Obstetrics & Gynecology 2018;52(S1):10-10. 
11. Limpitikul WB, Dick IE, Tester DJ et al. A precision medicine approach to 
the rescue of function on malignant calmodulinopathic long-qt syndrome. 
Circulation research 2017;120(1):39-48. 
12. Laschke MW, Menger MD. Life is 3d: Boosting spheroid function for tissue 
engineering. Trends in Biotechnology;35(2):133-144. 
13. Ong CS, Zhou X, Han J et al. In vivo therapeutic applications of cell 
spheroids. Biotechnology Advances 2018;36(2):494-505. 
14. Ong CS, Fukunishi T, Nashed A et al. Creation of cardiac tissue exhibiting 






15. Itoh M, Nakayama K, Noguchi R et al. Scaffold-free tubular tissues created 
by a bio-3d printer undergo remodeling and endothelialization when implanted in 
rat aortae. PloS one 2015;10(9):e0136681. 
16. Yurie H, Ikeguchi R, Aoyama T et al. The efficacy of a scaffold-free bio 3d 
conduit developed from human fibroblasts on peripheral nerve regeneration in a rat 
sciatic nerve model. PloS one 2017;12(2):e0171448. 
17. Kizawa H, Nagao E, Shimamura M, Zhang G, Torii H. Scaffold-free 3d bio-
printed human liver tissue stably maintains metabolic functions useful for drug 
discovery. Biochemistry and Biophysics Reports 2017;10:186-191. 
18. Moldovan L, Barnard A, Gil CH et al. Ipsc-derived vascular cell spheroids 
as building blocks for scaffold-free biofabrication. Biotechnol J 2017. 
19. Moldovan NI, Hibino N, Nakayama K. Principles of the kenzan method for 
robotic cell spheroid-based three-dimensional bioprinting. Tissue engineering Part 
B, Reviews 2017;23(3):237-244. 
20. Heidenreich PA, Albert NM, Allen LA et al. Forecasting the impact of heart 
failure in the united states: A policy statement from the american heart association. 
Circulation Heart failure 2013;6(3):606-619. 
21. Udelson JE, Stevenson LW. The future of heart failure diagnosis, therapy, 
and management. Circulation 2016;133(25):2671-2686. 
22. Oh H, Ito H, Sano S. Challenges to success in heart failure: Cardiac cell 





23. Sanganalmath SK, Bolli R. Cell therapy for heart failure: A comprehensive 
overview of experimental and clinical studies, current challenges, and future 
directions. Circulation research 2013;113(6):810-834. 
24. Michler RE. Stem cell therapy for heart failure. Cardiology in review 
2014;22(3):105-116. 
25. Huang P, Tian X, Li Q, Yang Y. New strategies for improving stem cell 
therapy in ischemic heart disease. Heart failure reviews 2016;21(6):737-752. 
26. Patel AN, Mittal S, Turan G et al. Revive trial: Retrograde delivery of 
autologous bone marrow in patients with heart failure. Stem cells translational 
medicine 2015;4(9):1021-1027. 
27. Martino H, Brofman P, Greco O et al. Multicentre, randomized, double-
blind trial of intracoronary autologous mononuclear bone marrow cell injection in 
non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the 
miheart study). European heart journal 2015;36(42):2898-2904. 
28. Guijarro D, Lebrin M, Lairez O et al. Intramyocardial transplantation of 
mesenchymal stromal cells for chronic myocardial ischemia and impaired left 
ventricular function: Results of the mesami 1 pilot trial. International journal of 
cardiology 2016;209:258-265. 
29. Wang F, Guan J. Cellular cardiomyoplasty and cardiac tissue engineering 





30. Murphy SV, Atala A. 3d bioprinting of tissues and organs. Nature 
biotechnology 2014;32(8):773-785. 
31. Smith AS, Macadangdang J, Leung W, Laflamme MA, Kim DH. Human 
ipsc-derived cardiomyocytes and tissue engineering strategies for disease modeling 
and drug screening. Biotechnology advances 2017;35(1):77-94. 
32. Bobak M, Guanglei X, Simon D, James KM. Current progress in 3d printing 
for cardiovascular tissue engineering. Biomedical Materials 2015;10(3):034002. 
33. Yeong WY, Sudarmadji N, Yu HY et al. Porous polycaprolactone scaffold 
for cardiac tissue engineering fabricated by selective laser sintering. Acta Biomater 
2010;6(6):2028-2034. 
34. Gaetani R, Doevendans PA, Metz CH et al. Cardiac tissue engineering using 
tissue printing technology and human cardiac progenitor cells. Biomaterials 
2012;33(6):1782-1790. 
35. Gao L, Kupfer M, Jung J et al. Myocardial tissue engineering with cells 
derived from human induced-pluripotent stem cells and a native-like, high-
resolution, 3-dimensionally printed scaffold. Circulation research 2017. 
36. Pati F, Jang J, Ha DH et al. Printing three-dimensional tissue analogues with 
decellularized extracellular matrix bioink. Nature communications 2014;5:3935. 
37. Norotte C, Marga FS, Niklason LE, Forgacs G. Scaffold-free vascular tissue 





38. Lian X, Hsiao C, Wilson G et al. Robust cardiomyocyte differentiation from 
human pluripotent stem cells via temporal modulation of canonical wnt signaling. 
Proceedings of the National Academy of Sciences 2012;109(27):E1848–E1857. 
39. Little MA, Jones NS. Sparse bayesian step-filtering for high-throughput 
analysis of molecular machine dynamics. Quantitative Biology 2010. 
40. Chartrand R. Numerical differentiation of noisy, nonsmooth data. ISRN 
Applied Mathematics 2011;2011:11. 
41. Uosaki H, Fukushima H, Takeuchi A et al. Efficient and scalable 
purification of cardiomyocytes from human embryonic and induced pluripotent 
stem cells by vcam1 surface expression. PLoS ONE 2011;6(8):e23657. 
42. Noguchi R, Nakayama K, Itoh M et al. Development of a three-dimensional 
pre-vascularized scaffold-free contractile cardiac patch for treating heart disease. 
The Journal of heart and lung transplantation : the official publication of the 
International Society for Heart Transplantation 2016;35(1):137-145. 
43. Zhu R, Blazeski A, Poon E, Costa KD, Tung L, Boheler KR. Physical 
developmental cues for the maturation of human pluripotent stem cell-derived 
cardiomyocytes. Stem cell research & therapy 2014;5(5):117. 
44. Zhu R, Millrod MA, Zambidis ET, Tung L. Variability of action potentials 
within and among cardiac cell clusters derived from human embryonic stem cells. 





45. Matsuura K, Utoh R, Nagase K, Okano T. Cell sheet approach for tissue 
engineering and regenerative medicine. Journal of controlled release : official 
journal of the Controlled Release Society 2014;190:228-239. 
46. Masumoto H, Sakata R. Cardiovascular surgery for realization of 
regenerative medicine. General thoracic and cardiovascular surgery 
2012;60(11):744-755. 
47. Masuda S, Shimizu T. Three-dimensional cardiac tissue fabrication based 
on cell sheet technology. Advanced drug delivery reviews 2016;96:103-109. 
48. Sakaguchi K, Shimizu T, Okano T. Construction of three-dimensional 
vascularized cardiac tissue with cell sheet engineering. Journal of controlled release 
: official journal of the Controlled Release Society 2015;205:83-88. 
49. Martin I, Wendt D, Heberer M. The role of bioreactors in tissue engineering. 
Trends in biotechnology 2004;22(2):80-86. 
50. Chiu LL, Iyer RK, Reis LA, Nunes SS, Radisic M. Cardiac tissue 
engineering: Current state and perspectives. Frontiers in bioscience (Landmark 
edition) 2012;17:1533-1550. 
51. Stevens KR, Pabon L, Muskheli V, Murry CE. Scaffold-free human cardiac 






52. Stevens KR, Kreutziger KL, Dupras SK et al. Physiological function and 
transplantation of scaffold-free and vascularized human cardiac muscle tissue. 
Proceedings of the National Academy of Sciences 2009;106(39):16568-16573. 
53. Rogozhnikov D, O'Brien PJ, Elahipanah S, Yousaf MN. Scaffold free bio-
orthogonal assembly of 3-dimensional cardiac tissue via cell surface engineering. 
Scientific reports 2016;6:39806. 
54. Hirt MN, Hansen A, Eschenhagen T. Cardiac tissue engineering: State of 
the art. Circulation research 2014;114(2):354-367. 
55. Borovjagin AV, Ogle BM, Berry JL, Zhang J. From microscale devices to 
3d printing: Advances in fabrication of 3d cardiovascular tissues. Circulation 
research 2017;120(1):150-165. 
56. Lee JH, Han YS, Lee SH. Long-duration three-dimensional spheroid culture 
promotes angiogenic activities of adipose-derived mesenchymal stem cells. 
Biomolecules & therapeutics 2016;24(3):260-267. 
57. Kelm JM, Ehler E, Nielsen LK, Schlatter S, Perriard JC, Fussenegger M. 
Design of artificial myocardial microtissues. Tissue Eng 2004;10(1-2):201-214. 
58. Trieschmann J, Bettin D, Haustein M et al. The interaction between adult 
cardiac fibroblasts and embryonic stem cell-derived cardiomyocytes leads to 






59. Zhou P, Pu WT. Recounting cardiac cellular composition. Circulation 
Research 2016;118(3):368-370. 
60. Pinto AR, Ilinykh A, Ivey MJ et al. Revisiting cardiac cellular composition. 
Circulation Research 2016;118(3):400-409. 
61. Morrissette-McAlmon J, Blazeski A, Somers S, Kostecki G, Tung L, 
Grayson WL. Adipose-derived perivascular mesenchymal stromal/stem cells 
promote functional vascular tissue engineering for cardiac regenerative purposes. 
Journal of tissue engineering and regenerative medicine 2017:n/a-n/a. 
62. Carvalho E, Verma P, Hourigan K, Banerjee R. Myocardial infarction: Stem 
cell transplantation for cardiac regeneration. Regenerative medicine 
2015;10(8):1025-1043. 
63. Cambria E, Pasqualini FS, Wolint P et al. Translational cardiac stem cell 
therapy: Advancing from first-generation to next-generation cell types. npj 
Regenerative Medicine 2017;2(1):17. 
64. Ye L, Zimmermann WH, Garry DJ, Zhang J. Patching the heart: Cardiac 
repair from within and outside. Circulation research 2013;113(7):922-932. 
65. Ong CS, Zhou X, Huang CY, Fukunishi T, Zhang H, Hibino N. Tissue 
engineered vascular grafts: Current state of the field. Expert review of medical 
devices 2017;14(5):383-392. 
66. Ong CS, Yesantharao P, Huang CY et al. 3d bioprinting using stem cells. 





67. Dor V, Di Donato M, Sabatier M, Montiglio F, Civaia F. Left ventricular 
reconstruction by endoventricular circular patch plasty repair: A 17-year 
experience. Seminars in thoracic and cardiovascular surgery 2001;13(4):435-447. 
68. Pok S, Stupin IV, Tsao C et al. Full-thickness heart repair with an 
engineered multilayered myocardial patch in rat model. Advanced healthcare 
materials 2017;6(5). 
69. Duran AG, Reidell O, Stachelscheid H et al. Regenerative medicine/cardiac 
cell therapy: Pluripotent stem cells. The Thoracic and cardiovascular surgeon 
2018;66(1):53-62. 
70. Kannan S, Kwon C. Regulation of cardiomyocyte maturation during critical 
perinatal window. The Journal of physiology 2018. 
71. Mummery CL. Perspectives on the use of human induced pluripotent stem 
cell-derived cardiomyocytes in biomedical research. Stem cell reports 
2018;11(6):1306-1311. 
72. Birket MJ, Ribeiro MC, Kosmidis G et al. Contractile defect caused by 
mutation in mybpc3 revealed under conditions optimized for human psc-
cardiomyocyte function. Cell reports 2015;13(4):733-745. 
73. Makita N, Yagihara N, Crotti L et al. Novel calmodulin mutations 






74. Crotti L, Johnson CN, Graf E et al. Calmodulin mutations associated with 
recurrent cardiac arrest in infants. Circulation 2013;127(9):1009-1017. 
75. Qi LS, Larson MH, Gilbert LA et al. Repurposing crispr as an rna-guided 
platform for sequence-specific control of gene expression. Cell 2013;152(5):1173-
1183. 
76. Gilbert LA, Larson MH, Morsut L et al. Crispr-mediated modular rna-
guided regulation of transcription in eukaryotes. Cell 2013;154(2):442-451. 
77. Yanamandala M, Zhu W, Garry DJ et al. Overcoming the roadblocks to 
cardiac cell therapy using tissue engineering. Journal of the American College of 
Cardiology 2017;70(6):766. 
78. Benam KH, Dauth S, Hassell B et al. Engineered in vitro disease models. 
Annual Review of Pathology: Mechanisms of Disease 2015;10(1):195-262. 
79. Strauss DG, Blinova K. Clinical trials in a dish. Trends in Pharmacological 
Sciences 2017;38(1):4-7. 
80. Nie J, Hashino E. Organoid technologies meet genome engineering. EMBO 
reports 2017;18(3):367-376. 
81. Driehuis E, Clevers H. Crispr/cas 9 genome editing and its applications in 






82. Ong CS, Fukunishi T, Zhang H et al. Biomaterial-free three-dimensional 
bioprinting of cardiac tissue using human induced pluripotent stem cell derived 
cardiomyocytes. Sci Rep 2017;7(1):4566. 
83. Schwank G, Koo BK, Sasselli V et al. Functional repair of cftr by 
crispr/cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell stem cell 
2013;13(6):653-658. 
84. Pulgarin DAV, Nyberg WA, Bowlin GL, Espinosa A. Crispr/cas systems in 
tissue engineering: A succinct overview of current use and future opportunities. 
Curr Trends Biomedical Eng & Biosci 2017;5(4):555670. 
85. Park S, Lui C, Jung W-H et al. Mechanical characterization of hipsc-derived 
cardiac tissues for quality control. Advanced Biosystems 2018;2(12):1800251. 
86. Zimmerman TG, Lanier J, Blanchard C, Bryson S, Harvill Y. A hand 
gesture interface device. SIGCHI Bull 1986;18(4):189-192. 
87. Pensieri C, Pennacchini M. Overview: Virtual reality in medicine. 2014 
2014;7(1). 
88. Chinnock C. Virtual reality in surgery and medicine. Hospital technology 
series 1994;13(18):1-48. 
89. Bao X, Mao Y, Lin Q et al. Mechanism of kinect-based virtual reality 
training for motor functional recovery of upper limbs after subacute stroke. Neural 





90. Yiannakopoulou E, Nikiteas N, Perrea D, Tsigris C. Virtual reality 
simulators and training in laparoscopic surgery. International journal of surgery 
(London, England) 2015;13:60-64. 
91. Yoo S-J. 3d printing in medicine of congenital heart diseases. 3D Print Med 
2015;2. 
92. Hibino N. Three dimensional printing: Applications in surgery for 
congenital heart disease. World journal for pediatric & congenital heart surgery 
2016;7(3):351-352. 
93. Vukicevic M, Mosadegh B, Min JK, Little SH. Cardiac 3d printing and its 
future directions. JACC Cardiovascular imaging 2017;10(2):171-184. 
94. Wierzbicki M, Drangova M, Guiraudon G, Peters T. Validation of dynamic 
heart models obtained using non-linear registration for virtual reality training, 
planning, and guidance of minimally invasive cardiac surgeries. Medical image 
analysis 2004;8(3):387-401. 
95. Kim Y, Kim H, Kim YO. Virtual reality and augmented reality in plastic 
surgery: A review. Archives of plastic surgery 2017;44(3):179-187. 
96. Ripley B, Kelil T, Cheezum MK et al. 3d printing based on cardiac ct assists 
anatomic visualization prior to transcatheter aortic valve replacement. Journal of 





97. Ong CS, Loke YH, Opfermann J et al. Virtual surgery for conduit 
reconstruction of the right ventricular outflow tract. World journal for pediatric & 
congenital heart surgery 2017;8(3):391-393. 
98. Linte CA, Moore J, Wedlake C et al. Inside the beating heart: An in vivo 
feasibility study on fusing pre- and intra-operative imaging for minimally invasive 
therapy. International journal of computer assisted radiology and surgery 
2009;4(2):113-123. 
99. Mitsouras D. Medical 3d printing for the radiologist. RadioGraphics 
2015;35. 
100. Olivieri LJ, Krieger A, Loke YH, Nath DS, Kim PC, Sable CA. Three-
dimensional printing of intracardiac defects from three-dimensional 
echocardiographic images: Feasibility and relative accuracy. J Am Soc 
Echocardiogr 2015;28(4):392-397. 
101. Farooqi KM, Sengupta PP. Echocardiography and three-dimensional 
printing: Sound ideas to touch a heart. J Am Soc Echocardiogra 2015;28. 
102. Mahmood F, Owais K, Taylor C et al. Three-dimensional printing of mitral 
valve using echocardiographic data. JACC Cardiovascular imaging 2015;8(2):227-
229. 
103. Stepan K, Zeiger J, Hanchuk S et al. Immersive virtual reality as a teaching 






104. Marks SC. Recovering the significance of 3-dimensional data in medical 
education and clinical practice. Clin Anat 2001;14(1):90-91. 
105. Beck J, Rohde S, el Beltagy M et al. Difference in configuration of ruptured 
and unruptured intracranial aneurysms determined by biplanar digital subtraction 
angiography. Acta Neurochir 2003;145(10):861-865. 
106. Hademenos GJ, Massoud TF, Turjman F, Sayre JW. Anatomical and 
morphological factors correlating with rupture of intracranial aneurysms in patients 
referred for endovascular treatment. Neuroradiology 1998;40(11):755-760. 
107. Lall RR, Eddleman CS, Bendok BR, Batjer HH. Unruptured intracranial 
aneurysms and the assessment of rupture risk based on anatomical and 
morphological factors: Sifting through the sands of data. Neurosurg Focus 
2009;26(5). 
108. Ma BS, Harbaugh RE, Raghavan ML. Three-dimensional geometrical 
characterization of cerebral aneurysms. Ann Biomed Eng 2004;32(2):264-273. 
109. Sadatomo T, Yuki K, Migita K, Taniguchi E, Kodama Y, Kurisu K. 
Morphological differences between ruptured and unruptured cases in middle 
cerebral artery aneurysms. Neurosurgery 2008;62(3):602-608. 
110. Sportillo D, Paljic A, Boukhris M, Fuchs P, Ojeda L, Roussarie V. An 
immersive virtual reality system for semi-autonomous driving simulation: A 





of the 9th International Conference on Computer and Automation Engineering: 
ACM;2017. p. 6-10. 
111. Slater M. Place illusion and plausibility can lead to realistic behaviour in 
immersive virtual environments. Philosophical transactions of the Royal Society of 
London Series B, Biological sciences 2009;364(1535):3549-3557. 
112. Slater M. Enhancing our lives with immersive virtual reality. Frontiers in 
Robotics and AI 3 2016;74. 
113. Sutherland IE. A head-mounted three dimensional display. Proceedings of 
the December 9-11, 1968, Fall Joint Computer Conference, Part 1 (New York, 
NY:ACM), 757-764 1968. 
114. Castelvecchi D. Warped worlds in virtual reality. Nature 
2017;543(7646):473-473. 
115. Sousa M MD, Paulo S, Matela N, JOrge J, Lopes DS. Vrrrroom: Virtual 
reality for radiologists in the reading room. In Proceedings of the 2017 CHI 
Conference on Human Factors in Computing Systems 2017:4057-4062. 
116. 2018 Fetal cardiac abnormalities: Screening, evaluation, and pregnancy 
management - uptodate. Available at https://www.uptodate.com/contents/fetal-
cardiac-abnormalities-screening-evaluation-and-pregnancy-management.  







118. Carvalho JS, Ho SY, Shinebourne EA. Sequential segmental analysis in 
complex fetal cardiac abnormalities: A logical approach to diagnosis - carvalho - 
2005 - ultrasound in obstetrics & gynecology - wiley online library. 26 2005(105-
111). 
119. Rajiah P, Mak C, Dubinksy TJ, Dighe M. Ultrasound of fetal cardiac 
anomalies. American Journal of Roentgenology 2011;197(4). 
120. Kleinman CS, Donnerstein RL, DeVore GR et al. Fetal echocardiography 
for evaluation of in utero congestive heart failure. The New England Journal of 
Medicine 2010;306:568-575. 
121. Small M, Copel JA. Indications for fetal echocardiography | springerlink. 
Pediatric Cardiology 2004;25(3):210-222. 




123. Yuan SM. Fetal cardiac interventions: An update of therapeutic options. 
Rev Bras Cir Cardiovasc 2014;29(3):388-395. 
124. Tworetzky W, McElhinney DB, Reddy VM, Brook MM, Hanley FL, 
Silverman NH. Improved surgical outcome after fetal diagnosis of hypoplastic left 





125. Lee W, Comstock CH. Prenatal diagnosis of congenital heart disease: 
Where are we now? Ultrasound Clinics 2006;1(2):273-291. 
126. Schultheis MT, Rizzo AA. The application of virtual reality technology in 
rehabilitation. Rehabilitation Psychology 2001;46(3):296-311. 
127. Wiederhold BK, Wiederhold MD. Virtual reality therapy for anxiety 
disorders: Advances in evaluation and treatment.; 2005. 
128. Laver K, George S, Thomas S, Deutsch JE, Crotty M. Virtual reality for 
stroke rehabilitation. Stroke 2012. 
129. Reddy UM, Filly RA, Copel JA. Prenatal imaging: Ultrasonography and 
magnetic resonance imaging. Obstet Gynecol 2008;112(1):145-157. 
130. Gallagher AG, Cates CU. Virtual reality training for the operating room and 
cardiac catheterisation laboratory. The Lancet 2004;364(9444):1538-1540. 
131. Vining DJ, From the Department of Radiology B-GSoM, Winston-Salem, 
NC, Liu K et al. Virtual bronchoscopy: Relationships of virtual reality 
endobronchial simulations to actual bronchoscopic findings. CHEST 
1996;109(2):549-553. 
132. Qui T-m, Zhang Y, Wu J-S et al. Virtual reality presurgical planning for 
cerebral gliomas adjacent to motor pathways in an integrated 3-d stereoscopic 






133. Marescaux J, Clément JM, Tassetti V et al. Virtual reality applied to hepatic 
surgery simulation: The next revolution. Ann Surg 1998;228(5):627-634. 
134. J X, N S, RW Y et al. Three-dimensional virtual reality surgical planning 
and simulation workbench for orthognathic... - abstract - europe pmc. Europe PMC 
2000;15(4):265-282. 
135. Stadie A, Kockro R, Reisch R. Virtual reality system for planning 








Dr. Chin Siang Ong was born in Singapore. He obtained his medical degree 
(MBBS) from the Yong Loo Lin School of Medicine, National University of 
Singapore in 2010. He subsequently joined the National University Health System 
(NUHS) (Singapore) General Surgery Residency Program, before joining the 
NUHS Cardiothoracic Surgery Residency Program. During this time, he also 
served as a Medical Officer in the Singapore Civil Defence Force (Rank: Captain 
(Dr)), as well as a volunteer doctor in humanitarian relief missions to the 
Philippines with the International Committee of the Red Cross and the Singapore 
Red Cross. 
 
In August 2015, Chin Siang began his PhD in Cellular and Molecular Medicine at 
the Johns Hopkins School of Medicine in Baltimore, Maryland, USA. During his 
PhD, he was awarded the John A. Hawkins Top Scoring Abstract Award at the 
Congenital Heart Surgeons' Society Annual Meeting (2016), the American Heart 
Association (AHA) Council on Cardiovascular Surgery and Anesthesia  Top Ten 
Abstract Travel Grant Award (2016), the 23rd Annual Talalay-Gott Cardiac 
Research Prize (2017) (“Awarded annually to a cardiac surgical research resident 
at Johns Hopkins Medical Institutions for the most outstanding research by a 





Association (GSA) Memorial Cash Prize and the Johns Hopkins GSA Student 
Travel Award (2017). He was also awarded the Tan Kah Kee Postgraduate 
Scholarship and the AHA Predoctoral Fellowship (Priority Score: 1.39. Percentile 
Rank: 0.25%. Cut-off: 19.90%) in 2017. 
 
After completing his PhD, Chin Siang will be starting a research fellowship in the 
Division of Cardiac Surgery at the Massachusetts General Hospital, Harvard 
Medical School in Boston, Massachusetts, USA, from April 2019. 
